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Summary 
Biomedical engineering arose out of the collaboration of medical doctors, biologists and 
engineers and substantially accelerated advances in medicine. Researchers in this field strive to 
improve medical care through the development of diagnostic tools and devices, prosthetics, surgical 
tools and robots, and tissue engineering. The latter one seeks regeneration or restoration of a 
damaged or diseased tissue. 
Materials used on or in human body must fulfill several divergent requirements. Firstly, 
they should provide mechanical support by offering sufficient mechanical strength, on a scale 
commonly found in synthetic polymers. Secondly, they should be biologically compatible and for 
instance trigger cell recognition usually attributed to natural polymers. One material type that 
captures both requirements are spider silk-based materials. Their unique chemistry and structure 
give spider silk fibers extraordinary mechanical properties and no immune response is induced in 
the body. Inherent cell recognition (eukaryotic and prokaryotic) of most native spider silks is poor, 
but if required, cell binding motives can be added using a biotechnological approach to produce 
recombinant spider silk proteins, which can further be processed into various morphologies. 
The objective of this dissertation was to exploit the beneficial properties of coatings, films, 
nonwovens and self-rolling bilayers made of recombinant spider silk proteins to widen the scope of 
their use in biomedical engineering. Spider silk scaffolds were investigated for loading with 
bioactive agents, use in heart muscle and nerve regeneration and as enzyme container.  
Accurate delivery of sensitive biological substances can improve cell behavior on scaffolds 
for tissue engineering. In the first project electrospun nanofibers with their inherent advantages of 
high porosity and surface-to-volume ratio were loaded with green fluorescent protein (GFP) as a 
bioactive agent model. Its fluorescence is structure dependent and common solvents used for 
electrospinning and post-treatment of silk destroyed GFP’s structure. Therefore, an aqueous 
electrospinning and post-treatment process was developed, which allowed a mild encapsulation and 
kept the structural integrity of GFP. The fast release of GFP could be inhibited or slowed down by 
genetic modification giving the system a broader application window. 
Post-surgical infections are a life-threatening risk and the increase in antibiotic resistant 
bacteria prove the need for alternatives. The second project investigated the antibacterial properties 
of spider silk coated selenium nanoparticles alone and encapsulated in silk films. Selenium 
nanoparticles are effective against gram-positive bacteria. By applying a coating of spider silk, the 
scope could be widened to gram-negative bacteria. Low doses of the coated nanoparticles killed 
Escherichia coli without impairing eukaryotic cell viability. 
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The body’s capability of cardiac repair after a myocardial infarct is poor and materials to 
assist cardiac regeneration are desperately needed. Thus, in the third project, the behavior of primary 
cardiac cells on spider silk films was investigated. The secondary structure content and the water 
contact angle of these films was found to be in a suitable range. Cell studies showed that silk films 
are non-toxic and provoke no pharmacologic effect. Furthermore, cardiac cells grown on these silk 
films showed required cell-to-cell communication and responded properly to extracellular stimuli, 
thus, laying the foundation for use of silk in cardiac tissue engineering. 
Injuries of the peripheral nerve system still show an inacceptable recovery rate. Thus, in the 
fourth project, bilayers of spider silk and chitosan were self-rolled into tubular structures to act as 
nerve guidance conduits. The tubes were either lined with a silk film containing a cell-recognition 
motif or aligned silk nanofibers, or an anisotropic collagen cryogel was encapsulated filling out the 
luminal space. The mechanical properties of the collagen cryogel are in the range of healthy 
peripheral nerves. Nerve cells could be entrapped by the gentle rolling process and their 
differentiation was achieved inside of the tubes, allowing the formation of neurite outgrowths. The 
aligned structures even triggered orientation of these neurite outgrowths in longitudinal direction, 
as is required in nerve repair. 
In the fifth project, these self-rolling tubular structures were optimized to encapsulate 
enzymes. They were shown to be stable in relevant organic and aqueous solutions and to possess a 
molecular weight cut-off above 20 kDa. Hence, these enzyme containers allowed the entrapment of 
enzymes, while substrates, intermediates and/or products can diffuse freely through the tube wall. 
This allowed to exchange the surrounding media without removing the enzymes, thereby saving 
often costly enzymes and enabling the design of a flow-through system. Reaction rates were slowed 
down, but longer reaction times were observed. Thus, this system can protect enzymes and may be 
useful for applications in biodiagnostics.  
Through this work, we showed that recombinant spider silk-based materials have a high 
potential in several fields of biomedical engineering. The processability into various morphologies 
and the precise control over the protein sequence makes it an interesting option for diverse 
applications. This thesis only gives a small glimpse at the scope of possibilities and more is yet to 
come.  
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Zusammenfassung 
Die Biomedizintechnik entstand durch die Zusammenarbeit von Ärzten, Biologen und 
Ingenieuren und beschleunigte so signifikant die Weiterentwicklung der modernen Medizin. 
Wissenschaftler in diesem Bereich streben eine Verbesserung des Gesundheitssystems durch die 
Entwicklung von Diagnoseinstrumenten, Prosthesen, chirurgischen Werkzeugen/Robotern und 
Geweberegeneration an, welche auf eine komplette Regeneration oder Wiederherstellung von 
geschädigtem oder erkranktem Gewebe abzielt. 
Materialien, welche am und im Körper eingesetzten werden, müssen viele divergente 
Anforderungen erfüllen. Einerseits sollten sie mechanische Stabilität in einem Bereich bieten, der 
üblicherweise bei synthetischen Polymeren zu finden ist. Andererseits sollten die Polymere 
biokompatibel sein und zum Beispiel von Zellen erkannt werden, ein Attribut, dass üblicherweise 
natürlichen Polymeren zugeschrieben wird. Bei einer Materialart verschwimmen diese Grenzen, da 
es die Vorteile von beiden Seiten vereint – spinnenseidenbasierte Materialien. Die einzigartige 
Chemie und Struktur verleiht Spinnenseidenfasern außergewöhnliche mechanische Eigenschaften 
und zusätzlich lösen sie keine Immunantwort aus. Die meisten natürlichen Spinnenseiden werden 
weder von eukaryotischen noch von prokaryotischen Zellen erkannt. Durch die Entwicklung eines 
biotechnologischen Prozesses zur Herstellung rekombinanter Seidenproteine, können, wenn 
gewünscht, zellbindende Motive genetisch hinzugefügt werden. Auch können rekombinante 
Seidenproteine in verschiedene Morphologien prozessiert werden. 
Ziel dieser Arbeit war es, die vorteilhaften Eigenschaften von Beschichtungen, Filmen, 
Vliesen und selbstrollenden Röhrchen basierend auf rekombinant hergestellten 
Spinnenseidenproteinen zu nutzen, um deren Anwendungsmöglichkeiten in der Biomedizintechnik 
auszuweiten. Spinnenseidengerüste wurden mit bioaktiven Substanzen beladen, für die Anwendung 
in der Herzmuskelregeneration, als Nervenleitstruktur, sowie als Enzymkontainer untersucht. 
Präzise Positionierung sensibler bioaktiver Substanzen kann das Zellverhalten an 
Gerüststrukturen für die Geweberekonstruktion verbessern. Im ersten Projekt wurden 
elektrogesponnene Nanofasern, welche nicht nur eine vorteilhafte hohe Porosität, sondern auch ein 
hohes Oberflächen-Volumen-Verhältnis aufweisen, mit grün fluoreszierendem Protein (GFP) als 
Modell für bioaktive Moleküle beladen. Die GFP Fluoreszenz ist strukturabhängig und gängige 
Lösungsmittel fürs Elektrospinnen und die Nachbehandlung von Seidennanofasern zerstören diese. 
Deshalb wurde ein wässriges Spinn- und Nachbehandlungsverfahren entwickelt, welches eine 
sanfte Verkapselung und somit die Erhaltung der GFP Struktur ermöglichte. Die rasche Freisetzung 
des GFP konnte mit Hilfe genetischer Modifikation verhindert oder deutlich verlangsamt werden 
und ermöglicht somit dem System einen breiteren Anwendungsbereich. 
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Postoperative Infektionen sind ein lebensbedrohendes Risiko und die rapide Vermehrung 
antibiotikaresistenter Keime erfordern die Entwicklung von Alternativen. Das zweite Projekt 
untersuchte die antibakteriellen Eigenschaften von seidenbeschichteten Selen-Nanopartikeln allein 
und eingebettet in Seidenfilmen. Die Wirkung gegen gram-positive Bakterien der Selen-
Nanopartikel konnte durch die Beschichtung mit Spinnenseide auch auf gram-negative Bakterien 
ausgeweitet werden. Schon kleinste Dosen der beschichteten Nanopartikel töteten erfolgreich 
Escherichia coli, ohne einen schädlichen Einfluss auf eukaryotische Zellen aufzuweisen.  
Die Fähigkeit des menschlichen Körpers, den Herzmuskel nach einem Herzinfarkt zu 
regenerieren, ist nicht vorhanden und es werden händeringend neue Materialien zur Förderung der 
Regeneration gesucht. Darum wurde im dritten Projekt das Zellverhalten von primären 
Herzmuskelzellen auf unterschiedlichen Seidenfilmen untersucht. Die Zusammensetzung der 
Sekundärstruktur sowie der Wasserkontaktwinkel waren in einem geeigneten Bereich. Es konnte 
gezeigt werden, dass Seidenfilme weder giftig sind noch pharmakologische Effekte hervorrufen. 
Zusätzlich zeigten die auf den Filmen wachsenden Herzmuskelzellen für das Herz notwendige Zell-
Zell-Kommunikation und reagierten angemessen auf extrazelluläre Stimulation, wodurch die 
Grundlage für die Verwendung von rekombinanten Spinnenseidenmaterialien in der 
Herzmuskelgeweberegeneration gelegt werden konnte. 
Verletzungen peripherer Nerven zeigen noch immer einen inakzeptablen Genesungsgrad. 
Im vierten Projekt wurden daher Röhrchen durch einen selbstrollenden Mechanismus von einer 
Doppelschicht aus Spinnenseide und Chitosan hergestellt, um als Nervenleitstruktur zu agieren. 
Dafür wurden die Röhrchen entweder mit einem Seidenfilm mit zellbindendem Peptid oder mit 
ausgerichteten elektrogesponnenen Nanofasern ausgekleidet, oder ein anisotropes Kollagen 
Cryogel wurde umrollt, wodurch der gesamte Hohlraum ausgefüllt wurde. Die mechanischen 
Eigenschaften von Kollagen Cryogelen lagen im Bereich von gesunden peripheren Nerven. Durch 
den sanften Roll-Prozess konnten Nervenzellen behutsam eingefangen und direkt in den Röllchen 
differenziert werden. Die ausgerichteten Nanofasern und die Cryogele ermöglichten sogar die 
Ausbildung von gerichtetem Neuriten-Auswuchs, welcher in der Nervenregeneration nötig ist. 
Im fünften Projekt wurden diese selbstrollenden Röhrchen optimiert, um Enzyme darin 
einzuschließen. Es konnte gezeigt werden, dass die Röhrchen stabil sind gegenüber relevanten 
organischen und wässrigen Lösungen und die Diffusion von Molekülen über 20 kDa verhindern. 
Daher konnten Enzyme eingeschlossen werden, wobei deren Substrate, Intermediate und/oder 
Produkte durch die Wand der Röhrchen diffundieren konnten. Die Enzymkontainer ermöglichten 
den Austausch des umgebenden Mediums, ohne das Enzyme zu entfernen, wodurch nicht nur oft 
teure Enzyme gespart werden, sondern auch Durchflusssysteme generiert werden könnten. Die 
ZUSAMMENFASSUNG 
5 
Reaktionsraten wurden durch die doppelte Diffusion verlangsamt, dafür konnten längere 
Reaktionszeiten beobachtet werden. Somit kann dieses System eingesetzt werden, um Enzyme zu 
schützen. Weitere Anwendungen im Bereich der Biodiagnose wären denkbar. 
In dieser Dissertation konnte gezeigt werden, dass Materialien aus rekombinanten 
Spinnenseidenproteinen hohes Potential in verschiedenen Bereichen der Biomedizintechnik 
aufweisen. Die Möglichkeit, Spinnenseide in verschiedenste Morphologien zu verarbeiten, 
kombiniert mit der Fähigkeit, die Sequenz der Spinnenseide präzise kontrollieren zu können, macht 
Spinnenseide zu einem interessanten Material für unterschiedliche Anwendungen. Diese Arbeit gibt 
nur einen kleinen Einblick in die Vielfalt an Anwendungsmöglichkeiten, und viele weitere 
spannende Entwicklungen werden erwartet.  
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1 Introduction 
 
1.1 Biomedical engineering 
In the 17th century the power relationship of science and church was shifted in favor of 
science paving the way for modern medicine. First steps included preventative medicine by for 
example increasing hygiene standards.1 Later, by the end of the 19th century, also curative medicine 
came into play by beginning with medication and surgery. As the knowledge requirement for all 
fields grew, different specialty fields were found – one of them being biomedical engineering 
(BME).  
 
 
Figure 1: Research focuses of biomedical engineering (BME): BME is an interdisciplinary field 
containing 14 subfields as defined by the Biomedical Engineering Society (BMES).2  
 
 Scientists working in BME use engineering principles and try to adapt them for medical 
applications. As a result, the application window is very broad and includes fourteen subfields as 
depicted in Figure 1.2 Exemplarily, scientists in BME developed medical electronic devices like 
smart wearable sensors for health monitoring3, cardiac pacemakers4, hearing aids, X-ray machines, 
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ultrasound or positron emission tomography. Other devices are concerned with measuring and 
administering substances in blood as for example blood chemistry sensors, infusion pumps or 
automated delivery of insulin.2 
Challenges currently tackled by BME are the ageing population, accidental injuries and 
monetary restrictions. The ageing population is associated with problems like arthritis in joints5, 
cardiovascular diseases6, organ failure7, or neurological diseases like Alzheimer’s disease8. The 
success of the treatments varies for example, joints can be replaced by hard, inorganic materials, 
which are unable to restore the or integrate with the host tissue. Thus, the ailment is eased, but not 
treated. Organs can be replaced by autografts (e.g. nerve repair) or allografts (e.g. liver, heart or 
kidney), whereby an autograft can result in the loss of function at the donor site and allografts 
usually result in foreign body response, and the immune-system must be suppressed to avoid 
implant rejection. Here, tissue engineering (TE) another big field in BME comes into play, which 
reflects the repair, restoration and regeneration of living tissue by using biomaterials, cells and 
factors.9 One development in TE is biofabrication, which uses emerging technologies like 3D 
bioprinting. Thereby, 3D tissue-like structures are prepared in vitro by precisely depositing 
biomaterials and cells to control cell-material and cell-cell interaction.10 Hereby, the aim is not only 
to develop technologies for in vivo use, but also for in vitro modelling for example to screen new 
pharmaceutical drugs for their safety.  
 Accidental injuries are age-independent and include peripheral nerve damage, bone 
fracture, ligament tear, skeletal muscle damage or burns.11 The success of the treatment depends on 
the severity of the ailment as well as on the age of the patient. Some of these injuries can even be 
cured completely for example in bone fracture the fractured parts are aligned and immobilized by 
a plaster cast allowing the bone to heal. A further issue worth mentioning is the increase in costs of 
superior and often personalized medical treatments. When we take peripheral nerve repair as an 
example, it takes a very skilled surgeon to introduce the conduit and then later, the patient requires 
physical therapy to help restore complete function. It is obvious, that only a small fraction of the 
population worldwide is in the privileged position to be able to afford such a treatment. In third 
world countries the focus still lies on disease prevention by for instance improving water quality, 
providing education and developing vaccines for e.g. vector-borne diseases like malaria.12 This is a 
first step into the right direction, but more needs to be done. 
 In summary, BME is a rapidly growing field showing many advances, which not only help 
to prolong, but also to increase the quality of a patient’s life. Many inventions entered the public 
health care system already. Several new developments are still in an early phase, and translation to 
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clinics is awaited. Clearly, the monetary issue has to be solved, to ensure high quality treatment for 
a wide mass of patients.   
 
1.2 Biomaterials 
A biomaterial is “defined as any substance (other than a drug) or combination of substances, 
synthetic or natural in origin, which can be used for any period of time, as a whole or as a part of a 
system which treats, augments, or replaces any tissue, organ, or function of the body” according to 
the National Institutes of Health (1980s).13 This includes metals e.g. titanium alloys used for joint 
replacement14, ceramics e.g. calcium orthophosphates used in dental applications15 and polymers. 
 
1.2.1 Polymers  
 Polymers are often used in biomedical applications as they not only offer a wide variety of 
physico-chemical properties, but in addition can be transferred into several morphologies ranging 
from thin polymer sheets to complex 3D constructs to suit applications in all branches of BME. In 
order to be used in or on human body, the polymers must be biocompatible and nonimmunogenic. 
Synthetic polymers in general provide good mechanical properties and frequently allow for control 
of the molecular weight. Polymers like silicone, poly(acrylate), poly(vinyl alcohol) (PVA) or 
poly(ethylene glycol) (PEG) can be used for applications, where no to slow degradation is 
required.9, 16 Aliphatic polyesters as for example poly(glycolic acid) (PGA), poly(lactic acid) (PLA; 
poly(L-lactic acid) (PLLA) and poly(D-lactic acid) (PLDA)), polycaprolactone (PCL) or 
poly(hydroxyalkanoates) (PHAs) (Figure 2) gained interest especially in the field of tissue 
engineering, as they show reasonable biodegradability. Problematic hereby is, that they commonly 
show bulk degradation kinetics instead of surface erosion, thus, the body has no chance to slowly 
replace the scaffold. Further, these polyesters degrade into acidic products not only reducing the pH 
in the surrounding tissue, but also accelerating the degradation of the scaffold.17-20 To avoid this, 
polymers such as poly(phosphazenes) have been developed, which degrade into pH neutral 
products.21 Synthetic polymers also lack inherent cell-binding motifs. Thus, cell-recognition sites 
must either be added during synthesis or the polymer must be coated with natural biopolymers like 
fibronectin22. Another option is to use them for applications, where cell-binding is not required for 
example PCL has been used as a dermal filler in form of microcapsules embedded in a 
carboxymethylcellulose matrix (Ellansé®23), as a root canal filling (Resilon24) or blended with PGA 
as a surgical suture material (Stratafix Spiral from Ethicon25). PLLA has been used as medical 
implants in form of pins, screws, suture anchors, rods or miniplates26. 
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Figure 2: Synthetic and natural polymers. Chemical structures of several polymers investigated for 
biomedical applications are shown. Polydimethylsiloxane, polyacrylate and polyvinyl alcohol are not 
biodegradable, polyethylene glycol is degradable if n < 1500 and poly(organophosphazene) backbone 
degrades into pH neutral ammonia and phosphate, “R” is commonly an O- or N-linked organic rest. The 
polyesters depicted are examples of the most commonly used ones in biomedical applications (PGA, 
PLA, PCL an PHAs), the “R” in poly(hydroxyalkanoates) refers to an aliphatic rest. Polysaccharides 
shown here are naturally derived polymers and made of sugar units connected via O-glycosidic bonds. 
They can be linear as agar, alginate, cellulose, chitin, chitosan and hyaluronic acid or branched like 
dextran. Proteins are made of amino acid chains connected via amide bonds. The “R” here varies 
between the different amino acids. 
 In order to overcome the limitations of synthetic polymers, biopolymers of natural origin 
are heavily investigated. These can be divided into three main groups, namely proteins, 
polysaccharides and deoxyribonucleic acids (DNAs).27 Examples of commonly used natural 
polymers are hyaluronic acid, starch, cellulose, alginate, dextran, chitin, chitosan, agar, fibronectin, 
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collagen, gelatin, soy and silk (Figure 2).16, 18, 28, 29 These natural polymers show advantages in terms 
of biocompatibility and biodegradability, as the degradation products – amino acids and sugars are 
commonly found in our body. In addition, these biopolymers often present recognition sites for cells 
e.g. RGD sequence in fibronectin.30 The major problem of natural biopolymers is that they suffer 
from poor mechanical properties (compared to synthetic polymers), limited control over 
physicochemical properties, batch-to-batch variations, scale-up difficulties and problems in 
sterilization.17, 18, 29, 31, 32 Collagen from natural sources is already used in patients for wound 
dressing e.g. BioPadTM made of native equine collagen33 or collagen sheets and particles from 
Maiden Biosciences made of bovine collagen34. Materials that combine extraordinary mechanically 
properties with biocompatibility and biodegradability are based on spider silk and will be discussed 
in more detail in the following chapter. 
 To date, only a few commercial applications using a single biopolymer were developed. 
Especially, in case of bigger constructs and more complicated structures, a single material seldom 
fulfills all necessary requirements. Hence, the development of a multi-component system 
comprising several polymers, factors (e.g. growth factors) and/or helping cells (e.g. Schwann cells 
in nerve regeneration35) will be necessary.29 
 
1.2.2 Silk  
1.2.2.1 Natural silk 
Silk was recognized early on, well before the 18th century, to be a viable material to be used 
as surgical thread or wound dressings.36-38 At the time, the people recognized that there is no 
abnormal secretion (pus), swelling or redness. Today it is known that silk is biocompatible and 
hypoallergenic, and it continues to be highly regarded as biomaterial. 
Silks are described by Craig39 as “fibrous proteins containing highly repetitive sequences of 
amino acids”, which “are stored in the animal as a liquid and configure into fibers when sheared or 
‘spun’ at secretion”. The remarkable part here is, that the fibrous silk proteins are processed out of 
highly concentrated solutions, usually typical for glues and unusual for other fibrous proteins like 
collagen.39 Silks evolved independently in different organisms possessing different structural 
characteristics designed for the desired purpose, probably evoked due to variable evolutionary 
pressures.40, 41 The driving mechanism behind the properties of different silks is the secondary 
structure. The secondary structure depends on the primary amino acid sequence, which is in silk 
proteins rich in glycine, alanine and/or serine. Commonly, silk materials show either a high α-
helical or β-sheet content. Insect silk proteins can adopt five protein structures, namely extended β-
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sheet, cross β-sheet, coiled-coil, collagen triple helix and polyglycine II and can be produced in 
dermal or labial glands or Malpighian tubules.42 So for example, lacewings use silk for production 
of egg stalks to protect the eggs from predators. This silk consists of cross β-sheets giving the egg 
stalk incredible bending stiffness. Honeybees on the other hand use silk for lining the nests and 
cocoons. These silks are not meant to withstand high forces and are therefore rich in α-helices. 
Silkworms produce silk as a cocoon to protect themselves during metamorphosis. This protection-
silk is made of crystalline patches embedded in an amorphous matrix.42 
Spiders are the only known animals producing up to seven different types of silks for various 
applications i.e. aggregate silk is used as glue for prey capturing and is very sticky, cylindriform 
silk is used to prepare egg cocoons and is very stiff, and major-ampullate silk also known as the 
“lifeline” of the spider, is strong as steel, but possesses a high toughness.43 Spiders possess different 
glands for all the silk types they produce and depending on the amino acid composition and the 
spinning process, the different functions of the silks are realized.41, 44 The most investigated spider 
silk is major ampullate silk consisting primarily of two protein classes, namely major ampullate 
spidroin 1 and 2 (MaSp1 and 2). The MaSp proteins consist of a repetitive core domain flanked by 
non-repetitive terminal domains. The repetitive unit of the core domain exhibits an amphiphilic 
nature comparable to block-co-polymers consisting of a GGX and GPGXX (only in MaSp2) rich 
part and a poly(A) sequence. The latter one forms β-sheets and –crystals, which are embedded in 
an amorphous but still strongly orientated region formed by the GGX/GPGXX-part.40, 45 This 
structural arrangement is the reason that silk is not brittle like other structures with high crystallinity, 
but possesses extraordinary mechanical properties. The amorphous regions enable elastic 
deformations, whereby the crystalline parts give the fiber the necessary strength resulting in very 
high toughness.46, 47 
 
1.2.2.2 Recombinant silk 
Bombyx mori (B. mori) silk can be obtained by large scale farming, but for spiders or insects, 
harvesting natural silk is tedious work. Generally farming suffers from batch-to-batch variations 
and the possibility of impurities.48 Especially problematic with farming of spiders is that they are 
territorial, cannibalistic and male spiders are often consumed after mating. Further, silk quality 
depends on the spider’s nutrition, age and well-being.49-51 Still, it has been shown that natural silk 
from Nephila spiders can be used in combination with decellularized porcine veins to prepare nerve 
guidance conduits.52 Farming of lacewing flies or bees would be more convenient, but the amounts 
of silk produced by these animals are minuscule that harvesting in reasonable amounts is not 
feasible.53 Therefore, biotechnological approaches have been developed, which allow for protein 
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production in large amounts with consistent quality and biological safety. Within the last 15 years 
recombinant silk production was established in Escherichia coli (E.coli) and yeast, and certain 
variants are mass-produced and can be purchased.54  
 Recombinant silk production can be divided into the following steps: (I) Determination of 
the natural DNA sequence; (II) Design of recombinant DNA; (III) Cloning of the vector; (IV) 
Transformation of the host organism; (V) Fermentation and/or protein production; (VI) Purification 
of the protein.55 Different host organisms from unicellular pro- or eukaryotes to multicellular plants 
or animals can be used, whereby the size of the protein, its necessity for post-translational 
modifications as well as their folding play a role.56, 57 Several groups developed recombinant silk 
proteins and variants thereof (Figure 3) e.g. 4RepCT58, 59, 6mer and 15mer60-62, rMaSp1/2 or 1F9 
and rS1/963-66; recombinant insect silk proteins e.g. moth silk EAEFN5/10
67, honey bee silk AmelF1-
468, 69, hornet silk Vssilk1-470, 71 or lacewing silk N[AS]8C
72, 73. Further, transgenic silkworm silk 
was developed like for example L-RGDSx2 fibroin74, 75, SELP-47K and SLEP-815K76-78 or 
[(AGSGAG)4E8AS]4
79, 80. 
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Figure 3: Schematic summary of various recombinantly produced spider and insect silks. Several of 
these silks show variations by the addition of N-, C- or intermediate tags, mainly used to trigger certain 
cell interactions like for instance the addition of an RGD-, IKVAV-, YGSR-, VN-, FN-tag to improve 
cell attachment. 
INTRODUCTION 
15 
In this work, the focus was on the Araneus diadematus’ MaSp2 derivative eADF4(C16) 
(engineered Araneus diadematus fibroin 4) and variations thereof. The repetitive unit of the core 
domain of MaSp2 was used as a template for the C-module. This C-module was then repeated 16 
times to obtain the artificial silk protein eADF4(C16) (Figure 4).  Each C-module holds a glutamic 
acid residue, giving the whole protein an overall negative charge.81 In order to increase cell 
adhesion, an integrin binding RGD-tag was added to create eADF4(C16)-RGD.82 Further, the 
glutamic acid was exchanged by lysine rendering it into the positively charged eADF4(κ16).83 
 
 
Figure 4: Scheme of recombinant eADF4(C16) production. The repetitive core domain of Araneus 
diadematus fibroin 4 (ADF4) was used as a template to obtain the C-module. The engineered ADF4 
(eADF4(C16)) was created by repeating this C-module 16 times. After back translation of the amino 
acid sequence and codon optimization for use in E. coli it was inserted into a plasmid containing also a 
gene for antibiotic resistance for selection. Then the host was transfected, and protein production 
induced. Several purification steps are necessary to obtain the pure protein powder, which can be 
processed into several morphologies. Reproduced with permission.84 Copyright 2018, WILEY-VHC 
Verlag GmbH & Co. 
 
1.2.2.3 Morphologies of recombinant silk and their applicability in BME  
Recombinant silk is usually obtained in form of a lyophilized powder in case of 
biotechnological produced silk proteins or fibers in case of transgenic silkworms. Recombinant silk 
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proteins can further be processed into different morphologies, namely films, micro- and nanofibers, 
foams, hydrogels, capsules and particles as shown in Figure 5.84 By far the most studied 
morphology are flat films as they are convenient for screening for biochemical features, 
cytocompatibility and physical characterization of the designed silk. Only a small amount of 
material is required to cast, dip- or spray-coat the required substrate and allow for high-throughput 
experiments. Especially, the effect of incorporation of cell binding peptides like RGD, IKVAV, 
YIGSR or other sequences from vitronectin (VN), vascular endothelial growth factor (VEGF), 
silaffin-derived R5 tag or antibiotics were studied in films using cell lines, primary cells, stem cells 
and subcutaneous pockets in vivo.82, 85-91 Furthermore, implants were successfully coated with silk 
films e.g. coating of silicone implants92, 93 or catheters94, 95 to reduce the negative side effects of the 
foreign body response or thrombotic fouling. 
Micrometer fibers of recombinant silk protein were prepared either by wet or biomimetic 
spinning96, 97 and self-assembly98. Fibers produced by self-assembly could be arranged into fiber 
meshes and compared to other morphologies in terms of fibroblast growth and maintenance of 
differentiation state.99 In vivo test of these fibers showed no toxicity and low immunogenicity.100 
Another source of micrometer sized fibers is B. mori silk. The cocoons from silkworms consist of 
one thread and after “degumming” plain silk fiber, also referred to as regenerated silk fibroin (RSF), 
is obtained and can be used in various forms (single strands, yarn, woven). Such transgenic RSFs 
were investigated as vascular grafts.86, 101, 102 Sub-micrometer and nanofibers are commonly 
produced by electrospinning, whereby a nonwoven fiber mat is produced. It was found that the fiber 
diameter plays a crucial role in cell attachment, whereby increasing fiber diameter increases cell 
attachment.103 Further, mixing with collagen was shown to be beneficial for stem cell 
differentiation.104 In general nonwoven fiber mats can be seen as the bridge between 2D films and 
3D networks.  
Characteristic for 3D foams are thin-walled pores. The pore diameter plays a crucial role in 
terms of nutrient/waste diffusion and vascularization.18, 105 In combination with recombinant silk 
proteins salt-leaching,63, 66, 79, 106 freeze-drying74 and an unknown mechanism99 were used for foam 
preparation. Next to in vitro tests with cell lines63, 66, 106, primary cells74, 99 or stem cells87, 107, studies 
on pancreatic island engineering88, 108 and femoral defects66, 79 were conducted. In order to closer 
resemble the natural extracellular matrix (ECM) hydrogels composed of >90 % water are gaining 
more and more interest. Here the polymer, i.e., silk protein can be physically or chemically 
crosslinked in solution. It was shown that cells could be encapsulated into self-assembling spider 
silk hydrogels, which could further be used as bioink in 3D printing.109, 110  
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A further approach are silk capsules and particles designed as mobile drug or gene delivery 
systems. Silk capsules enable the encapsulation of larger molecules and are formed by an emulsion 
process.111 Silk particles are commonly produced by salting-out in phosphate buffer, whereby the 
concentration of the silk and buffer solution as well as the mixing time play an important role in 
particle size.112 Particle loading was achieved by co-precipitation of the (model) drug with silk or 
by diffusion of the (model) drug into the particles. The desired cellular uptake was found to be 
increased using positively charged silk113 or specific cell binding peptides114. Herewith, cancer cells 
could be exclusively killed by delivery of doxorubicin.115 Additionally, several studies in terms of 
gene delivery were conducted showing for instance that Luciferase production was successfully 
induced in tumorous tissue in mice.116  
 
 
Figure 5: Processing routes of recombinant silk proteins. Different morphologies can be prepared from 
the lyophilized silk powder by using various techniques. Reproduced with permission.84 Copyright 
2018, WILEY-VHC Verlag GmbH & Co. 
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1.3 Tissue engineering 
“Tissue engineering is an interdisciplinary field that applies the principles of engineering and 
life sciences toward the development of biological substitutes that restore, maintain, or improve 
tissue function” according to Langer and Vacanti.17 The native physiological niche of cells entails 
complex physical and biochemical stimuli i.e. external and intrinsic cues determine cell fate. 
Physical cues include external forces, topography and substrate mechanics, whereby biochemical 
cues consist of the composition of the substrate and soluble molecules.117 Mimicking this 
environment is the goal of artificial tissue creation. Two approaches exist for their creation: (I) 
Bottom-up approach: Cells or cell clusters are allowed to assemble and mature into 3D structures 
by the aid of stimulation of chemical or mechanical nature. Thereby, the cells build extracellular 
matrix (ECM) as a scaffold for the tissue. An example for this approach is the assembly of cell 
spheroids to build organ like structures e.g. vessels118 (II) Bottom-down approach: A biomaterial 
scaffold is seeded with cells and the combination is allowed to mature by providing chemical or 
mechanical stimulation. Here, the biomaterial predetermines the structure and while slowly 
degrading, cells form their own ECM scaffold. An example for this second approach is the seeding 
of pancreatic beta cells into a mesoporous foam scaffolds for insulin production.108 For heart muscle 
tissue engineering both approaches are holding promises for example, cell-sheet patches created to 
cover the infarct-region and couple with the host tissue and also decellularized animal hearts seeded 
with cardiac cells were investigated. In nerve tissue engineering, the bottom-down approach seems 
straight-forward by creating a tubular structure to aid nerve regrowth. The addition of bioactive 
agents can further increase the success of artificial tissue formation in both approaches. 
Antibacterial agents decrease the risk of bacterial infections after implantation.119 Stimulating 
agents like growth factors can further promote cell growth, proliferation and differentiation and 
thereby for instance assist in healing processes.120 Figure 6 below depicts the TE triad composed of 
biomaterials, cells and signals. 
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Figure 6: Tissue engineering triad. The combination of the three pillars of tissue engineering – cells, 
signals and biomaterials – are pivotal for the success of a tissue engineering application. Biomaterials 
usually form the scaffold of the tissue engineering construct and can be of natural or synthetic origin. 
Cells are inevitably part of a tissue engineering construct, they can be the patient’s (autologous), a 
donor’s (allogeneic) or stem cells. Signals include mechanical and/or electrical stimulation as well as 
bioactive agents like growth factors and help bringing cells into the desired niche.  
 
1.3.1 Bioactive agents in tissue engineering 
Bioactive agents are compounds showing an effect on a living cell, tissue and/or 
organism.121 They comprise antibacterial agents e.g. antibiotics, silver or zinc nanoparticles (NPs) 
or antimicrobial peptides as well as molecules able to enhance healing processes like growth factors, 
cytokines, vitamins or anti-inflammatory molecules. Growth factors (GFs) and cytokines are 
signaling peptides acting via binding to specific transmembrane receptors i.e. do not cross cell 
membrane. This binding event starts a signaling cascade inside of the cell guiding cell fate. A GF 
for instance has effects on cell proliferation, intercellular signaling, chemotaxis, angiogenesis and 
ECM formation122, hence, could significantly promote artificial tissue formation. To induce their 
effect, GFs can be added directly in the cell suspension or applied in a bioreactor, which provides 
a hydrodynamic shear stress allowing to continuously refresh the GFs. Here the bioreactor approach 
seemed more efficient for instance allowing to build glossy and smooth cartilage-like tissue from 
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chondrocytes in PLA nanofibers in contrast to the rough tissue obtained by drop-seeding.123 
However, short half-lifes in the range of minutes to few hours124, temperature instability125 and 
degradation caused by fragmentation via oxidation or pH change126 as well as severe effects of 
concentration i.e. too little leads to the formation of non-homogeneous tissue127 and too much can 
cause abnormal tissue and inflammation128, hamper the direct application of GFs. Therefore, to 
protect and preserve the native structure of the bioactive molecule and allow for its steady release, 
several strategies were developed.  
In scaffold immobilization the GF is either physically or chemically entrapped within a 
scaffold. In physical entrapment like for instance in hydrogels, the GF is captured in a porous mesh 
and can be released by diffusion, swelling, erosion or osmotic effects, hence, usually useful for 
short term release.121 Chemical entrapment involves either affinity interactions or covalent bonds 
for example, heparin coating of a PCL structure allowed for entrapment of vascular endothelial GF 
(VEGF) leading to improved neovascularization compared to control without heparin.129 Another 
approach is programmed delivery using self-regulated systems for spatiotemporal release as for 
example pH triggered release, where a pH change in certain tissue areas induces release of the GF; 
molecular recognition, where the release is induced by biomolecule-recognition e.g. aptamer 
binding; or triggered delivery systems. The latter one uses external stimuli like for instance the 
application of magnetic fields on magnetic particles coated with the GF or light for release of 
photocleavable GF e.g. bone morphogenetic protein was photocleavable coupled to PEG and was 
shown to induce higher cellular metabolic activity in mesenchymal stem cells.121, 130 In a third 
approach bioactive molecules are entrapped within carriers like microtubes, crystals or more 
common in microspheres, nanoparticles (NPs) and micelles. These particulate systems can either 
be applied directly at the target site or integrated in a scaffold allowing for release via diffusion or 
bulk degradation e.g. PLGA NPs were loaded with VEGF and glial cell line-derived neurotrophic 
factor and used for treatment of Parkinson’s disease in rat brains showing a significant enhancement 
of neurons.131  
Another group of bioactive reagents improving the performance of TE constructs are 
antibacterial substances. Post implantation infections are one of the most common problems for 
instance infections were the cause of revisions in 20.4 % of total knee arthroplastry in US between 
2009 and 2013.132 The patient’s susceptibility to infections is increased as the immune system is 
hampered by the presence of a foreign body. Problematic hereby is that bacteria tend to form 
biofilms – an organized community of several bacterial strains enclosed in a self-made polymer 
matrix. A biofilm is the most successful form of life and hence is highly resistant to conventional 
drugs and the immune system.133 Therefore, conventional medication with antibiotics often give 
poor results as the antibiotic’s penetration ability to the infected site and further inside of the biofilm 
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is reduced not being able to kill it. Another point adding up to the problem is the increase in bacteria 
resistances to antibiotics by development of e.g. efflux-pumps, metabolic inactivation or restriction 
in uptake.134  
An efficient way to avoid bacterial infections can be achieved by hindering bacterial 
attachment onto implants. This can be done by applying an antibacterial coating. A passive coating 
can work as antiadhesive e.g. using PEG135 or nanotopographies thereby preventing the attachment 
of cells and proteins. Unfortunately, this coating also prevents attachment of eukaryotic cells, hence 
requires the addition of eukaryotic cell binding sequences.136 Active coatings kill bacteria via 
incorporation of bactericidal substances like antibiotics, silver, zinc or selenium NPs, quaternary 
ammonium salts (QAS), positively charged polymers like chitosan, or antimicrobial peptides.136 
The positive charge of the latter three leads to bacterial membrane permeabilization and cell 
lysis.117, 137 Antibiotics either kill bacteria or hinder their growth by interaction with cell wall 
synthesis, protein synthesis, interference with nucleic acid synthesis, inhibiting metabolic pathways 
or disrupting their membrane.138 The mode of action of NPs depends on the material they are made 
of and range from cell wall damage via growth inhibition by generation of reactive oxygen species 
to effects on protein synthesis.139 These bactericidal substances can be physically adsorbed or 
entrapped, or covalently attached within the active coating.  
As previously described in GF encapsulation, bactericidal substances can also be 
incorporated directly into the TE scaffold e.g. the synthetic peptide Tet213 or zinc oxide could be 
encapsulated in hydrogels of gelatin methacryloyl – tropoelastin and thereby decreased colonization 
by E.coli and Staphylococcus aureus (S. aureus).140 Another way to deliver antimicrobial 
substances can be achieved via polymeric particles, which protect their payload, are able to 
overcome cellular tissue barriers and promise a slow and sustained release to improve 
biodistribution and pharmacokinetics.141 Hence, they are more effective against biofilms as a high 
dose of antibacterial molecules can be delivered directly at the place of need e.g. formulation of 
liposomal antibiotics were shown to fuse with bacterial outer membrane delivering their contents 
directly inside of Pseudomonas aeruginosa cells142; or chitosan NPs loaded with vancomycin and 
decorated with folic acid showed enhanced uptake and efficiency against vancomycin resistant S. 
aureus.143 
All the described strategies depend on the interplay between the bioactive molecule, the 
encapsulating material and the cells involved. Due to the fact, that the stability of the bioactive 
agents as well as the cell requirements differ, not a single material or strategy will be able to fit all 
applications. Further, during tissue formation commonly several bioactive molecules are required 
in a time and dose dependent manner, which is far from what can be technically be realized up to 
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now. Thus, it is still a long way until such a complex system delivering the right molecule at the 
right time in the perfect concentration can be realized. However, more and more is learned about 
how materials can be modified and how pro- and eukaryotic cells react to certain stimuli pathing 
the way for generating optimized constructs for each application.   
 
1.3.2 Silk and bioactive agents 
Many studies focus on the incorporation of bioactive molecules into silk matrices. An easy 
approach is to immerse a silk matrix in a solution containing the bioactive molecule triggering their 
absorption into silk matrix. Transforming GF beta 3 (TGFβ-3) and bone morphogenetic protein-2 
(BMP-2) were absorbed on multi-layer B. mori and A. mylitta silk scaffold. Implantation into knee 
joints of Wistar rats yielded the formation of neo-matrix with glycosaminoglycans and collagen 
after 8 weeks.144 Another possibility is to blend silk proteins with the desired agent and subsequently 
process the mixture into the desired morphology. Using this approach RSF was blended with nerve 
growth factor (NGF) and subsequently cast into a film conduit. In vitro tests proved a significant 
outgrowth of neurites due to the slow release of the NGF over 3 weeks.145 Another study analyzed 
aligned electrospun fibers of RSF blended with brain-derived neurotrophic factor and VEGF. The 
constructs were implanted subcutaneously in adult mice and showed a release of the bioactive 
molecules over two weeks leading to de-novo innervation and vascularization without inducing a 
chronic inflammatory response.146 Further, injectable silk hydrogels were loaded with BMP-2 and 
VEGF. A minimal invasive approach was used to implant the GF loaded scaffold into rabbit 
maxillary sinus, where new bone was formed and angiogenesis was promoted.147 These two 
techniques – immersion and blending – can be rather easily realized, but often lead to an undesired 
quick release.  
In order to slow down the release, bioactive agents can first be encapsulated in spherical 
structures and then embedded in a matrix e.g. the antibiotic gentamycin sulfate was loaded onto 
gelatin microspheres, which were embedded into a silk matrix. This composite material exhibited 
slower release kinetics and stronger antibacterial effects against E. coli, S. aureus and Pseudomonas 
aeruginosa compared to the materials alone loaded with the antibiotic and was able to reduce burn 
infection in rats.148 In another interesting approach silver NPs with antibacterial properties were 
directly synthesized on a RSF matrix. Thereby the negatively charged amino acid residues acted as 
nucleation sites for positively charged silver ions and silver NPs were formed via UV-irradiation.149  
Covalent attachment of quaternary ammonium compounds onto silk fibroin was realized 
with the formation of 3-(trimethoxysilyl)-propyldimethyloctadecyl ammonium chloride. The 
antimicrobial function was not inhibited by the binding and the long chains allowed the interaction 
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of the compound with the bacterial cell wall eventually killing the cell.150 Further, covalent bonds 
can be introduced by creating genetic fusion proteins, which was done by genetically adding human 
neutrophil defensin 2 and 4 as well as hepcidin to recombinant spider silk protein 6mer. The self-
assembling features of silk were maintained and additionally antibacterial properties against E. coli 
and S. aureus without harming proliferation in mammalian cells were proven.61 The covalently 
attached antimicrobial peptide Cys-KR12 to electrospun RSF not only showed a reduction of 
several bacteria strains, but in addition showed an enhancement in proliferation of dermal 
fibroblasts and keratinocytes as well as immune-modulating properties assisting in wound 
healing.151 In a different study a non-natural azide bearing amino acid was incorporated into the 
recombinant 4RepCT spider silk protein. This azide group was used for copper catalyzed azide-
alkyne cycloaddition to add the antibiotic levofloxacin. With the acid-labile glycerol-ester linker a 
slow and steady antibiotic release could be achieved being effective against E. coli.89 
Silk matrices were successfully modified with diverse bioactive agents and underwent in 
vitro and in vivo studies. All studies incorporating GFs resulted in an improvement in cell behavior 
and/or tissue generation and the studies dealing with the addition of antibacterial agents illustrated 
bactericidal effects. It could be shown that dependent on the loading strategy, the agents were 
released either fast or slow providing adaptable systems for different requirements in TE. Hence, 
silk can be considered a promising material for bioactive agent delivery. 
 
1.3.3 Heart muscle regeneration 
The heart is a muscular, hollow organ enclosed by a protective sac, the pericardium. The 
heart walls are made of myocardium and endocardium. The heart is responsible for pumping blood 
through the circulatory system. This pivotal process supplies cells with oxygen and nutrients and 
removes metabolic wastes. In mammals the heart is built of four chambers, left and right atria (upper 
chambers) and ventricles (lower chambers). The left heart is responsible for pumping the oxygen 
enriched blood via arteries to all parts of the body (systemic circulation). The oxygen depleted blood 
from the systemic circulation reaches the right heart from where it is pumped to the lungs 
(pulmonary circulation) for gas exchange.152 The blood then enters the left heart again and the cycle 
restarts in healthy individuals. 
Heart failure is one of the main causes of death in industrialized nations usually resulting 
from a deficiency of cardiac cells.153 The different classes, characteristics and their impact on 
physical activity are shown in Table 1. According to the American Heart Association heart failures 
are categorized into left-sided, right-sided and congestive heart failure. In the left-sided heart failure 
insufficient blood is pumped through the system circulation. This can have two causes: (I) he left 
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ventricle cannot contract normally (reduced ejection fraction) or (II) the left ventricle is too stiff to 
relax normally and thus proper filling with blood is impeded (preserved ejection fraction). In the 
right-sided heart failure blood backs up in the veins due to reduced pumping power of the right 
ventricle. In the congestive heart failure fluid builds up in the body due to a reduced blood flow out 
of the heart.154  
 
Table 1: Classification of heart failure adapted from Baliga et al.155, 156  
NYHA 
Class 
Characteristics Impact on physical activity 
2-year Mortality 
(%) on ACE-I* 
I No heart failure - no rales or S3§ Asymptomatic – no limitation, 
no shortness of breath, fatigue or 
palpitations during physical 
activity 
10 
II Heart failure – rales (<50 % 
lungs), S3 and venous 
hypertension 
Slight limitations – shortness of 
breath, fatigue or palpitations 
during physical activity 
20 
III Severe heart failure – frank 
pulmonary edema, rales (>50 % 
lungs) 
Marked limitations – shortness of 
breath, fatigue or palpitations 
during activities of daily living 
30-40 
IV Cardiogenic shock – signs 
include hypotension and 
peripheral vasoconstriction 
Heart failure – often with 
pulmonary edema 
Symptoms at rest – shortness of 
breath, fatigue or palpitations 
40-50 
# New York Heart Association 
* angiotensin-converting enzyme inhibitors 
§ third heart sound – associated with heart failure 
 
The human left ventricle is made of 2-4 billion cardiomyocytes, and a single myocardial 
infarction can kill up to 25 % of these cells within a few hours.157 Other reasons for loss of cardiac 
cells are disorders of cardiac load e.g. hypertension or valvar heart disease, which lead to a cellular 
reduction over many years158. Further, ageing in general is already accompanied by a reduction by 
1 gram of myocardium per year even in the absence of a disease.159 The problem is that the heart is 
one of the organs showing least regenerative capacity153 with annual cardiomyocyte turnover rates 
of 1.9 % in adolescent, 1 % in middle aged and 0.45 % in old aged humans.160 Interestingly, human 
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cardiomyocytes react to pathological workloads like hypertension, valvar disease and post-
infarction overload by reinitiating DNA synthesis without a nuclear division and therefore, most 
possess polyploid nuclei.161, 162 A potential reason for their post-mitotic state in adult mammals is 
that the centrosomes of cardiac cells disassemble shortly after birth and thus, sending 
cardiomyocytes into a cell-cycle arrest.163 Another possible route for cardiomyocyte production, 
next to proliferation, is differentiation of cardiac progenitor cells (CPC). Although it was shown, 
that CPC are activated for instance in the case of an infarction and prompted to divide, migrate, 
experience lineage commitment and mitigate pathological damage,164 the rate is too slow with the 
additional issue of a severe reduction of cardiac progenitor cells during ageing.165 In summary, 
several studies offer a strong evidence for plasticity in human heart, but the processes of 
cardiomyocyte production are too slow to compensate for their loss. Therefore, strategies dealing 
with cellular reprogramming, stem cell therapy and tissue engineering are investigated (Figure 7).153 
Cellular reprogramming means that for instance the scar forming fibroblasts at the infarct 
site are reprogrammed and become cardiomyocytes. The idea seems very appealing, but an efficient 
and transgenic-free process as well as information on how normal these cardiomyocytes behave are 
still missing.153 Due to the insufficient cardiac cell regeneration in the body, stem cell (SC) therapy 
is a promising route for cardiac engineering. Extensive research went into analysis of the potential 
of pluripotent SCs like embryonic SCs (ESC) and human induced pluripotent SCs (hiPSC), which 
have the capability to differentiate into nearly all cell types, hence also cardiomyocytes. Problematic 
hereby is, that often these cells are immature and lack not only expression profile, but also 
morphology and function of ventricular cardiac cells.153 Another important point is that ESC 
therapies would be allogenic, thus, requiring immunosuppression.153 On the other hand, every 
hiPSC, which could be obtained by reprogramming of the patient’s somatic cells, is officially a new 
product that needs to undergo all safety studies before usage. The alternative could be a well-
characterized bank of several SC lines that can be matched according to human leukocyte antigen 
to reduce immune suppression to a minimum.166 A further issue that must be clarified before using 
PSCs is their chromosomal instability and the possibility of introduction of mutations that could 
cause a malignant transformation.166 Several clinical trials tested the treatment of heart failure 
patients with bone marrow derived SCs proposing the safety of the method. Unfortunately, only 
little improvement in myocardial structure and function was observed.165 Thus, using SC alone 
might not be the holy grail to cardiac repair, but the combination with a scaffold like in cardiac 
tissue engineering (TE) it might lead to a breakthrough in the field. 
One of the major objectives of cardiac TE is to produce functional heart muscle tissue, 
which is further transplanted on malformed or injured hearts to regain normal function.166 The 
expected advantages are a higher cell retention than in cell therapy167 and the possibility of quality 
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control before implantation166. Cardiomyocytes tend to beat spontaneously and possess the intrinsic 
capacity of forming 3D functional syncytia166 –promising features for TE. Further, it was found, 
that constructs containing mixtures of cardiomyocytes with nonmyocytes were able to develop three 
times higher forces than with cardiomyocytes alone.168 This might be due to an ECM mediated 
mechanism, as ventricular rat cardiac cells showed enhanced growth on ECM produced by 
fibroblasts.169 Thus, one approach to prepare an artificial heart is to decellularize a whole heart (here 
rat) by extended Langendorff perfusion leading to an almost complete removal of heart cells and 
leaving the connective tissue. This tissue possesses the right shape and can further be perfused, but 
a high mechanical stiffness was observed and repopulation with cells to regain full function remains 
a challenge.170 
Other approaches aim at the preparation of tissue patches – either based on a scaffold e.g. 
composite hydrogel from collagen and Matrigel with cardiac cells,171 stacked cell sheets e.g. by co-
culturing endothelial with cardiac cells and stacking three of these sheets172 or scaffold-free 
aggregates obtained e.g. by gyratory shaking in 6-well dish173. These patches are theoretically not 
limited in width or length, but – as in all tissue engineering applications – the thickness possesses a 
critical limit of about 80 µm if no vascularization is present.174 Although spontaneous 
vascularization of 3D cardiac constructs was observed with172, 173 and without168, 175 the addition of 
endothelial cells, pre-vascularization is required to obtain a reasonable thick construct of several 
millimeters. Another important factor in cardiac patches is the need for electric coupling with the 
host so that synchronized beating following the lead of pacemaker cells can be achieved. Therefore, 
often bigger implants are investigated to enable contact with healthy myocardium.176 Still, this is 
not an easy task as the heart’s epicardium, the epithelial cell layer on the graft’s surface and/or the 
formation of a cell-free ECM layer between host and implant can inhibit contacting of 
cardiomyocytes.171  
Another open question is the time point of transplantation. Electrical177 and mechanical178 
stimulation in vitro showed an enhancement in longitudinal orientation and alignment, hypertrophy 
and electromechanical function, thus, resulted in more mature constructs. Important here, even in 
good 3D constructs, cardiomyocytes are not showing a fully mature phenotype i.e. lacking densely 
packed contractile machinery175 and possessing unusual length/width ratio.179 However, greater cell 
differentiation leads to worse survival rates after transplantation.180 Thus, there is an ongoing search 
for optimal constructs that allow to fully regenerate heart function. 
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Figure 7: Routes investigated for heart muscle regeneration after myocardial infarct (grey patch on 
heart). First row: cellular reprogramming – fibroblasts in the scar tissue of the myocardial infarct should 
be reprogrammed to cardiac cells. Second row: stem cell (SC) therapy – stem cells are differentiated 
into heart cells and then injected into the scar tissue. Third row: tissue engineering (TE) – bottom-down 
approach: A scaffold is combined with heart cells (probably provided from SC differentiation) and the 
construct is implanted into the infarct site. Fourth row: TE – bottom-up approach: Cell sheets or 
aggregates are prepared and implanted onto the infarct site. 
 
1.3.4 Silk in heart muscle regeneration 
Lately, several studies using moth, silkworm and recombinant spider silk investigated their 
suitability for cardiac regeneration. In one of the first studies, B. mori silk fibroin was mixed with 
chitosan and/or hyaluronic acid. Sprayed microparticles were pressed and crosslinked with genipin. 
The cardiac patches were seeded with ratMSCs, and it was shown that growth rate and 
differentiation were superior on the hybrid patches.181 In the first follow up study patches from silk 
with hyaluronic acid pre-seeded with or without BMSC were implanted in rats onto induced 
myocardial infarcts. Especially the cell loaded constructs showed improvement of left ventricular 
modeling, low to no cytotoxic response, prevented apoptosis of cardiomyocytes, restored contractile 
proteins and stimulated the secretion of growth factors for cardiac repair.182 Further, silk and 
chitosan-hyaluronan patches without cells were implanted in rats onto myocardial infarcts showing 
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similar promising results than the previous study suggesting the suitability of hybrid silk constructs 
in cardiac regeneration.183 
Stoppel et al.184 examined anisotropic and isotropic B. mori sponges blended with cardiac 
tissue-derived ECM or collagen using atrial cardiomyocytes and hESCs derived cardiomyocytes 
and additional in vivo tests. The aligned structures in combination with ECM cues supported cell 
infiltration and vascularization in vivo as well as a functional phenotype in vitro.184 Castellano et 
al.185 compared electrospun silkworm silk with PCL, PLA, polyamide, poly(3-hydroxybutyrate) 
and non-crosslinked collagen membrane in terms of  cell compatibility using cardiac cells and MSC. 
Although cell attachment was comparable to controls, in vivo studies showed an encapsulation due 
to foreign body response and no prevention of negative remodeling after the myocardial infarct was 
observed.185 In another study, BMSC and menstrual blood derived SCs were seeded onto sponges 
from B. mori silk. They could show that the SCs attached and distributed well in the scaffold and 
in addition proliferation and the level of cardiac differentiation marker was higher than in 2D 
controls.186 Another group showed that cardiac progenitor cells seeded into anisotropic B. mori silk 
sponges distributed uniformly and synthesized a great quantity of  ECM. Analysis with qPCR 
revealed similar protein expression levels than in cardiac tissue, proving the possibility of 
resembling a stem cell niche driving efficiently cardiac progenitor cell commitment.187 
Antheraea mylitta silk coated on glass coverslips and in form of a foam was investigated 
using primary cardiomyocytes from postnatal rats. Cardiomyocytes efficiently attached, responded 
to extracellular stimuli, expressed connexin 43 (cell communication), exhibited aligned sarcomers 
(basic unit responsible for contraction) and coupled electrically with each other resulting in 
synchronous beating. Due to the inherent RGD domain in Antheraea mylitta silk, it outperformed 
B. mori silk in this study.188 In another study Antheraea assama silk was compared to B. mori silk 
by investigating neonatal cardiomyocytes on micro-grooved films. In general, Antheraea assama 
silk outperformed silkworm silk in terms of mechanical robustness, elasticity, cell compatibility 
and lower immunogenicity in vivo. The grooved structure allowed the production of aligned cell 
monolayers with an upregulation in several factors i.e. connexin 43, myosin heavy chain alpha and 
troponin I (maturation and functionality). Additionally, these layers could be stacked to form a 3D 
construct.189 
On the foam of the recombinant spider silk protein VN-4RepCT – an analog of 
Euprosthenops australis MaSp1 with a vitronectin tag – hESC could be successfully differentiated 
into cardiomyocytes. Under xeno-free conditions, markers for cardiac lineage were expressed.87 In 
another study materials made of the recombinant spidroins rS1/9, rS2/12 and the RGD variant of 
the latter one – all originating from Nephila species – were compared to silkworm silk. The 
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electrospun mats, especially the variants containing RGD, showed promising results when seeded 
with neonatal rat cardiomyocytes. The cells attached, grew and formed confluent layers, but also 
formed a cardiac syncytium and were shown to be fully functional, thus, capable of coordinated 
contraction.64  
In general, the low to no immune response, the slow biodegradation and the possibility to 
form various morphologies make silk a very interesting material in cardiac TE applications. The 
results using B. mori silk are slightly diverse, being not very persuading. The reason could be the 
missing cell binding motifs, as blends with other materials like collagen offering these binding 
moieties indicated positive results. Hereby, recombinant spider silk provides the advantage to 
genetically add such cell binding peptides like in rS2/12-RGDS triggering cell behavior. Further, 
recombinant silk can be produced in big amounts and in constant quality. Especially, the xeno-free 
preparation of 4RepCT and its variants seems promising. 
 
1.3.5 Nerve regeneration 
The nervous system is responsible for transmission of signals throughout the body by 
detecting environmental changes and responding to them. In higher developed organisms, it can be 
divided into two parts, namely the central nervous system (CNS) and the peripheral nervous system 
(PNS). The CNS consists of the brain and spinal cord and the PNS includes all nerve bundles 
connecting the CNS with the rest of the body. The PNS can be divided into sensory and motor 
division responsible for transport of information in form of chemical signals and electrical impulses 
from a receptor to the CNS or the CNS to effectors (muscle and glands), respectively.  
A peripheral nerve consists of several layers, whereby the smallest unit are neurons 
(Figure 8). A neuronal cell consists of a cell body and different extensions – the short ones are called 
dendrites and are responsible for sensing signals, the long ones can grow up to a meter, are called 
axon and are responsible for signal transmission.190 The axons can be covered by a myelin sheath 
as a protection as well as for faster signal transduction. These nerve fibers are enclosed by the 
endoneurium, a loose connective tissue. Numerous of these form a nerve bundle/fascicle, which in 
turn is covered by the perineurium. Several fascicles and blood vessels are bundled together by the 
epineurium forming a peripheral nerve.191  
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Figure 8: Peripheral nerve: Neuronal cells are composed of a cell body with two types of extensions: 
neurites (short extension for sensing signals) and axons (long extensions for signal transduction). In 
higher developed organisms, axons are often covered by a myelin sheath for protection and faster signal 
transduction. Such nerve fibers are enclosed by the endoneurium and several of these are then collected 
into fascicles surrounded by the perineurium. The fascicles, blood vessels and fibroblasts form the nerve 
trunk and are surrounded by the epineurium. 
 
Injuries at the peripheral nerve system can occur from vehicle or industrial accidents, 
penetrating trauma or falls and can lead to muscle paralysis or a complete or partial loss of motor 
functionality. Estimates assume approximately five million cases of peripheral nerve injuries every 
year.192 Robinson193 summarized in a Table the classifications of nerve injuries as described by 
Seddon194 and Sunderland195 including the pathology as well as the prognosis - this table is shown 
as Table 2.193 
  
INTRODUCTION 
31 
 
Table 2: Classification systems of nerve injuries as present by Robinson193 
Seddon 
classification 
Sunderland 
classification 
Pathology Prognosis 
Neurapraxia First degree Myelin injury or ischemia Excellent recovery in weeks to 
months 
Axonotmesis First degree Axon loss, variable stromal 
disruption 
Good to poor, depending upon 
integrity of supporting structures 
and distance to muscle 
 Second degree Axon loss, endoneurial tubes, 
perineurium and epineurium 
intact 
Good, depending upon distance 
to muscle 
 Third degree Axon loss, endoneurial tubes 
disrupted, perineurium and 
epineurium intact 
Poor, axonal misdirection, 
surgery may be required 
 Fourth degree Axon loss, endoneurial tubes 
and perineurium disrupted, 
epineurium intact 
Poor, axonal misdirection, 
surgery usually required 
Neurotmesis Fifth degree Axon loss, endoneurial tubes, 
perineurium and epineurium 
severed 
No spontaneous recovery, 
surgery required, prognosis after 
surgery not guaranteed 
 
The PNS reacts to an injury – crush or section – by active de- and regeneration. It begins 
with the Wallerian degeneration of the distal axon part.196 Hereby, first the axonal skeleton and then 
the myelin sheath degenerate. Macrophages infiltrate and clear the debris, promoting 
vascularization197 and axonal regeneration198. Schwann cells dedifferentiate into a pro-regenerative, 
nonmyelinating phenotype and start to proliferate and migrate. They express surface proteins, 
secrete neurotrophic factors and deposit basal lamina proteins e.g. laminin and fibronectin, to form 
bands of Büngner. This bands guide the way for reinnervation of the proximal part activated by 
certain signaling pathways.199, 200  If the gap between the distal and proximal part is too wide, fibrin 
deposition and scar tissue formation occurs in its way, limiting reinnervation. Thus, the nerve will 
not gain back its original function.200 In such cases, surgery can help, whereby a tension-free end-
to-end suture is favored for gap sizes smaller than one centimeter. For bigger gap sizes (20-80 mm) 
nerve autografts e.g. from the patient’s sural nerve, are the current gold standard.201 Hereby, the 
axons within in the autograft degenerate and leave a 3D network of ECM with aligned structures 
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that gives physical guidance and allows the ingrowth of the proximal nerve stump. In addition to 
this physical guidance, the autograft provides chemical and cellular signals i.e. neurotrophic factors 
and Schwann cells. Unfortunately, this treatment shows limitations in supply of donor nerve, results 
in donor morbidity, shows limited restoration function to the acceptor site, induces the risk of 
neuroma formation and needs time consuming surgery.192 The success rate, getting back good to 
excellent motor or sensory function, is below 50 percent.202 An attractive alternative are nerve 
guidance conduits (NGCs), which should provide a guidance similar to autografts along which the 
nerve stumps can regrow towards each other.203  
The ideal NGC is depicted in Figure 9. It is biocompatible, immunologically inert and 
biodegrades slowly to avoid foreign body reactions and scar tissue formation. The materials used 
should be flexible and soft and at the same time possess a high tensile strength mimicking the natural 
model – the ECM with its basal lamina.192 The tube should be semi-permeable. On the one hand, it 
should avoid infiltration of inflammatory cells and myofibroblasts, which would impede nerve 
regeneration by for instance depositing axon repulsive proteoglycans. On the other hand, they 
should allow diffusion of gases, vital nutrients and factors and permit revascularization to provide 
a good regenerative environment.204 Furthermore, the material should provide a physical guidance 
cue to lead the way for Schwann cells and growing axons, termed contact guidance theory.192 
Moreover, studies claimed beneficial effects on reinnervation upon the addition of bioactive 
molecules, ECM-like matrix, supporting cells and electrical conductivity. Bioactive molecules like 
neurotrophic factors assist the survival, growth and differentiation of neural cells. Ideally, these 
factors are released in controlled doses over an extended period of time to allow for long term 
repair.205 In order to resemble the natural environment of a peripheral nerve, ECM-like matrices 
containing for example collagen206, laminin or fibronectin207 were introduced. Cellular assistance 
can be provided by the introduction of Schwann cells. Autologous Schwann cells and stem cells, 
with the capability to differentiate into Schwann cells, gave promising results.192 Additionally, 
technical requirements concerning production, sterilization, long-term storage and surgical 
handling need to be met.35, 201  
Up to now, most FDA approved NGCs consist of a hollow tube and are made of synthetic 
polymers like for example PGA (Neurotube), PVA (SaluBridge/SaluTunnel), polyhydroxybutyrate 
(AxonScaff/Cellscaff/StemScaff), poly(DL-lactic-co-ε-caprolactone) (NeuroLac). Furthermore, 
collagen I was used as a tube forming material (NeuraGen, NeuroMend, NeuraWrap, 
NeuroMatrix/Neuroflex).208 These tubes fail in treatment of larger nerve gaps, probably due to the 
missing filling. In an attempt to solve this problem, NeuraGen 3D was developed. Here, the 
NeuraGen tube was filled with a collagen-glycosaminoglycan matrix.209 Another approach uses 
processed human nerve allograft (Avance® Nerve Graft) to provide a naturally derived NGC.210 
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However, current clinical data suggests that NGC show a similar performance than autologous 
nerve grafts for short gaps, but are still outperformed in large gaps (> 20 mm).200 A possible 
explanation could be the missing chemical and cellular signals, which did not yet obtain regulatory 
approval.192 
 
Figure 9: The optimal nerve guidance conduit (NGC). NGCs should provide a semi-permeable 
membrane, an ECM-like filling, physical guidance cues, support cells, bioactive molecules and 
electrical stimulation.  
 
1.3.5.1 Self-rolling tubular structures 
The fundamental part of an NGC is a tubular structure, which can be further equipped with 
the beforementioned bioactive molecules, supporting cells, guidance cues and ECM like filling. 
Post-preparational filling of tubes with these additives can be tricky. Therefore, a self-rolling 
approach, where the additives can be applied onto a film and rolling can be induced afterwards, 
would be beneficial.   
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Self-assembling mechanisms are a major driving principle of structure formation in nature 
and hence the concept of intelligent materials.211, 212 The idea is to mimic mechanisms observed in 
organ development, fruit growth and plant movement as for instance the closing mechanism in a 
Venus fly trap. A transition from concave to convex structure evoked by hydration allows the trap 
to close its “jaws” in only 100 ms.213, 214 The principle behind this natural mechanism is an 
inhomogeneous reaction of an either inherent inhomogeneous material or of the different layers of 
a multi-layer system in response to environmental stimuli like a change in pH, temperature, solvent, 
light, electric field or enzyme concentration.213, 215 In multi-layer systems the layers are termed as 
active and passive. The active layer responds to the environmental stimulus by swelling and thus, 
induces a change in the passive one. If the passive layer is hard, wrinkles and creases are formed, 
whereas if the passive layer is soft curling and rolling occurs to release the internal stress.216, 217  
Imitating this principle can be used to produce self-folding microconstructs, often referred to 
as microorigami. Advantages are not only the quick and reproducible fabrication but also the 
possibility to render the chemical properties as well as the morphology of the interior and exterior 
of the constructs.215, 217, 218 Pioneering work in the field of self-folding materials was performed by 
Jager et al.219 and Smela et al.220. They were the first working with metal-polymer films, which 
responded to an electric signal. Several more self-rolling approaches comprising metals were 
performed.221, 222 These are mainly interesting as microelectronic devices, though inapplicable in 
the field of biomedical engineering, as they show a limited biocompatibility and are non-
biodegradable. Thus, stimuli-responsive polymers were gaining more and more interest in this field. 
They respond to mild changes in their environment by undergoing dramatic changes in physico-
chemical properties as for instance a volumetric change due to swelling.223 Common intelligent 
polymers used in this field are pH-, thermo- or solvent responsive.215 Sometimes they are even 
multi-responsive, hence reacting to several stimuli like poly(N-isopropylacrylamide-co-acrylic 
acid) responding to temperature and pH.224 Poly(N-isopropylacrylamide) derivatives were often 
used and show an excellent performance as active polymer, but are not biodegradable.217, 224-227 
Therefore, biodegradable polymers like gelatin228, polysuccinimide218 or  silk229 were investigated 
as self-rolling tubes also for the use with cells.  
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1.3.6 Silk in nerve regeneration 
Several studies using silk fibroin or spider silk in combination with nerve and/or Schwann 
cells gave promising results. Schwann cells were cultured in the presence of silk fibroin extract 
fluid and no difference was observed compared to plain medium in terms of morphology, viability, 
proliferation and factor secretion suggesting very good biocompatibility of silk fibroin-based 
materials.230 Further, Schwann cells seeded onto electrospun silk fibroin non-woven mats exhibited 
more ordered and longer outgrowths as well as more extensive and more complex interconnections 
compared to polylysine.231 In another study, B. mori silk tubes were filled with Spidrex® fibers and 
implanted to bridge an 8 mm gap in rat sciatic nerve. After 12 weeks, the number of myelinated 
axons, gastrocnemius muscle interaction and hind paw stance (catwalk food print analysis) were 
comparable to that of animals with the autologous nerve graft control.232 Further, several studies 
investigated silk fibroin blends with natural or synthetic polymers like chitosan, collagen, 
tropoelastin, PLLA, poly(lactide-co-glycolide) (PLGA), poly(lactide-co-caprolactone) (PLCL), 
polyacrylamide or poly(p-dioxanone) as reviewed in200. An interesting study here used a lysine-
doped poly(pyrrole)/regenerated spider silk protein/PLLA/nerve growth factor (NGF) composite 
scaffold prepared by co-axial electro-spraying and -spinning. First tests with PC-12 cells were 
already successful in terms of biocompatibility, cell adhesion and stable conductivity and successive 
in vivo tests bridging a 2 cm sciatic nerve gap in rat showed a promotion in Schwann cell migration 
and axonal regrowth within 10 months.233 
Other studies investigated natural fibers from Nephila spiders as nerve guidance cues 
embedded with Schwann cells in Matrigel inside of acellularized veins.234 After this first successful 
study a 2 cm sciatic nerve defect in rats was bridged with and without Schwann cells and Matrigel. 
It was shown that all constructs lead to nerve regeneration within 6 months by guiding Schwann 
cell migration and proliferation and axonal re-growth.235 In a later study, a 6 cm tibial nerve defect 
in sheep was bridged with an acellularized pig vein construct filled with Nephila fibers and 
compared to autologous nerve grafts. No significant difference was observed in Schwann cell 
migration, axonal regrowth and remyelination including electrophysiological recovery.52 In an in 
vitro study, it was even suggested that these constructs are able to bridge a 15 cm gap.236 
Recombinant silk is scarcely used in peripheral nerve repair, and mainly in vitro studies are 
available. Neural stem cells were investigated on films of the Euprosthenops australis derived 
4RepCT protein and showed successful proliferation as well as maturation into neurons at the 
presence of bone morphogenetic protein.237 Films of the Nephila clavipes derived rMaSp1 protein 
supported growth of primary rat cortical neurons in terms of axon extension and network 
connectivity, and in addition, an increase in neural cell adhesion molecule expression was 
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observed.238 Foams of another Nephila clavipes derived protein rS1/9 film was implanted into 
midline dorsal subcutaneous areas in mice and promoted the ingrowth of nerve fibers and 
vascularized connective tissue elements.63  
Thus, silk seems to be a promising material for nerve regeneration not least because of its 
outstanding mechanical properties combined with biocompatibility. Especially, in terms of 
recombinant silk more investigations are necessary, to finally confirm its suitability in bridging 
nerve gaps. 
 
1.4 Bioinstrumentation 
According to Berkley Bioengineering, “Bioinstrumentation is the development of 
technologies for the measurement and manipulation of parameters within biological systems, 
focusing on the application of engineering tools for scientific discovery and for the diagnosis and 
treatment of disease”.239 Bioinstrumentation spans a wide field of commonly computer-assisted 
devices, biosensors being one of them. The basic principle of a biosensor is the transformation of a 
chemical information like the concentration of a certain analyte in the sample into an analytically 
useful signal. Hence, the two basic elements are the biological recognition system and a 
physicochemical transducer240 connected to a computer to produce a user-friendly read-out. The 
biological recognition element should be sensitive to the desired analyte and measure it with a high 
degree of selectivity,241 a feature often attributed to enzymes. 
 
1.4.1 Enzyme confinement 
Catalysts decrease the activation energy needed for a chemical reaction and thereby increase 
the reaction rate without being used up themselves. Thus, a catalyst changes the kinetics, but not 
the thermodynamics of a reaction, i.e., the equilibrium is achieved faster with a catalyst than 
without, but the equilibrium is not changed. A catalyst influences the reaction mechanism by 
forming an often otherwise instable intermediate with the reactant and thereby it lowers the potential 
energy. Nature is an expert in using biocatalysts, called enzymes, to perform enantiopure, site- and 
substrate-specific reactions in an all-aqueous system at body-friendly reaction conditions. Another 
essential part of nature’s ingenuity is its ability to run all reactions in a crowded environment i.e., 
synthetic reactions occur mainly in cells in our body, often in specific compartments thereof. This 
compartmentalization helps to organize reaction processes as well as it enhances efficiency 
thereof.242  
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 In an attempt to use this natural principle, enzymes are immobilized by either adsorbing or 
binding them to a surface, physically entrapping them in a matrix or encapsulating them in a 
container.243 Enzymes can be fixed onto a surface by adsorption to the surface via non-covalent 
interactions either directly with the surface or via affinity tags e.g. biotin coupled to the surface 
interacting with streptavidin bound to the enzyme. Further, enzymes can be bound covalently to a 
surface via an organic linker either directly connected to the surface using for instance crosslinkers 
like glutaraldehyde or to a soft coating like an amphiphilic bilayer.244 These methods commonly 
also allow to immobilize more enzymes to enable cascade reactions. Special systems were 
developed, to even precisely control the spatial arrangement of the enzymes e.g. a DNA origami 
nanotube was used to precisely position glucose oxidase (GOX) and horseradish peroxidase 
(HRP).245 For physically entrapment of enzymes in a matrix, the components are often mixed in 
liquid form and then processed into the matrix e.g. bioactive glasses were prepared by a sol-gel 
method encapsulating HRP in (alkylated) silica.246 In all these approaches care must be taken to not 
block the active site of the enzyme as this would cause a decrease or complete suppression of the 
catalytic activity. An advantage of immobilized enzymes is the ease in separating the product from 
the enzyme.  
Another approach are volume confined containers to encapsulate enzymes. Hereby, 
enzymes in solution are encapsulated in distinct compartments. The substrate can either be supplied 
by placing it directly with the enzyme into the container, by fusing two compartments like vesicles 
one filled with the enzyme and the other with the substrate, or by diffusion in semi-permeable 
containers.243 The membrane can protect the cargo from harmful, like for instance hydrolytically 
active substances in surrounding media. Realizations of such a system are depicted in Figure 10: (I) 
vesicles like liposomes from biological bilayers247, 248 or polymerosomes consisting of amphiphilic 
block copolymers249; (II) protein cages with proteinous boundaries like in prokaryotic 
microcompartments or virus capsids250; (III) reverse micelles for example formed by emulsions 
from ionic liquids or surfactants251; (IV) water-in-oil droplets forming semi-permeable capsules 
from amphiphilic molecules252; (V) polymer capsules like polyelectrolytes using a layer-by-layer 
approach to form a capsule around a removable template253; (VI) arrays of small reaction vessels 
prepared for instance by chemical etching254.  
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Figure 10: Schematic drawing of enzyme containers: liposome from an amphiphilic molecule e.g. (A) 
small unilamellar vesicle (diameter in tens of nanometer range) or polymerosome (diameter up to a few 
micrometers); (B) protein cage formed by proteinous boundaries e.g. virus capsid (diameter in the tens 
to hundreds nanometer range); (C) reverse micelle formed from an amphiphilic molecule e.g. 
phospholipid monolayer (diameter in tens of Ångström range);  (D) semi-permeable capsule formed 
from amphiphilic molecules in a water-in-oil system e.g. spider silk as described in the following chapter 
(diameter varies between systems from several up to hundreds of micrometer); (E) polymer capsuled 
formed by a layer-by-layer approach after template removal, usually a positively and negatively charged 
polymer are used consecutively e.g. poly(styrene sulfonate) (-) in combination with poly(allylamine 
hydrochloride) (+) (diameter varies from hundreds of nanometer to several micrometer); (F) array of 
small reactions vessels obtained by e.g. chemical etching containing usually one enzyme only (vessel 
diameter are a few micrometers and height from several hundred nanometers to a few micrometers) 
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1.4.2 Silk in enzyme confinements 
Matrices from silk fibroin were found to stabilize enzymes in liquid and solid form in terms 
of temperature, pH, electrodialysis, proteolysis, UV light, detergents and/or organic solvents. 
Mainly, bulk-loaded silk films were investigated, where silk and enzyme were simply mixed in 
liquid state and cast. This approach was often applied in the field of biosensors using redox 
enzymes. Hereby, an electrode was coated with a silk film containing the desired enzyme e.g. GOX, 
to monitor the amount of the substrate in a given analyte e.g. glucose level in blood.255 Further, 
porous silk fibroin membranes, sponges, microparticles, powders, fibers, woven fabrics and mats 
and even inks256 were prepared. These B. mori silk scaffolds were either kept as they are, if a water-
soluble system was required or rendered water insoluble by either alcohol treatment, water 
annealing, glutaraldehyde crosslinking or physical treatment. Several studies dealt with HRP and 
GOX but also other enzymes like lipase, cholesterol oxidase, tyrosinase, ribonuclease, alkaline 
phosphatase, uricase, L-asparakinase, heme proteins, phenylalanine ammonia-lyase, invertase, 
organophosphorus hydrolase and β-glucosidase were examined for industrial, diagnostic, medical 
and biosensor applications. Especially in terms of biosensors, the matrix permeability plays a crucial 
role and could be controlled via the secondary structure i.e. β-sheet content or addition of porogens 
e.g. PEG.257 All these systems have in common, that the enzymes are encapsulated within the silk 
network. The glassy dynamics suppresses enzyme’s mobility via β-relaxation processes, which 
prevents unfolding and mass transport of reactive species that would be necessary for 
degradation.258 Hence, a long storage life can be provided as well as a greater reusability.257 
In order to protect biologicals in solution, layer-by-layer silk fibroin capsules were used as 
a cage. Here two strategies were investigated: (I) pre-loading strategy, where a porous template like 
silica was loaded with the biological and after silk capsule formation, the core was removed259 and 
(II) post-loading strategy, where layer-by-layer microcapsule was formed from silk fibroin modified 
with either poly(lysine) (+) or poly(glutamic acid) (-), which allowed pH triggered permeability 
that could be used for encapsulation and release of the biosensing system260. Another approach used 
spider silk capsules for enzyme entrapment. Hereby, the amphiphilic silk protein self-assembled at 
an oil/water interface, thereby forming a nanometer-thin film, which was either immediately water 
insoluble, when toluene was used261, 262 or had to be post-treated in an ethanol/water bath, when 
silicon oil was used as an organic phase. This film protected the encapsulated β-galactosidase even 
against proteases, whereby the substrates as well as the products could diffuse freely. Additionally, 
α-complementation was used to control the activation of β-galactosidase. Therefore, the inactive 
enzyme precursor EA22 was encapsulated. Then the peptide ED28 could be added to the 
surrounding medium, which was able to diffuse through the capsule wall to activate the enzyme by 
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inducing dimerization.111 In another approach using recombinant spider silk esterase-2 was 
genetically coupled to the silk protein. This modified silk protein could then be self-assembled into 
nanofibrils or particles, retaining enzyme activity.263 
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2 Aim of the work 
Silk is a promising material for biomedical applications. Within this work the suitability of 
engineered Araneus diadematus fibroin 4 (eADF4(C16)) and variants thereof was investigated for 
use in the field of biomedical engineering. 
The first study aimed the development of an all aqueous electrospinning process for spider 
silk proteins. The morphology, secondary structure content and thermal behavior of the resulting 
nonwoven silk mat should be characterized and compared to nonwoven mats produced by 
previously established methods. Further, a model for a sensitive bioactive compound should be 
incorporated to investigate the ability of the process to preserve the molecules activity. 
The aim of the second study was to expand the bactericidal effect of selenium nanoparticles 
towards gram-negative bacteria. This should be realized by applying a silk coating. The morphology 
of coated nanoparticles as well as the secondary structure content of the silk coating should be 
characterized. The coated particles should be tested for their effect against gram-negative bacteria 
and on eukaryotic cells.  
The aim of the third study was to determine the potential of eADF4(κ16) films for heart 
muscle regeneration. The films should be characterized in terms of secondary structure content and 
water contact angle. Then cardiac cell response to these films should be investigated applying 
different conditions in order to determine their ability to attach, communicate, contract and their 
reaction to external stimuli. 
The fourth study aimed the characterization and development of a tubular structure for use 
as a nerve guidance conduit (NGC) in nerve regeneration. In order to assist re-growing peripheral 
nerves, it is beneficial, if the inside of the tube wall as well as its filling is adjustable. Therefore, a 
biodegradable self-rolling tubular structure should be developed, which allows for modifications of 
the inside tube wall with different silk types and morphologies as well as the addition of filler 
material. After optimization the tubes should undergo cell viability and differentiation studies to 
determine, if the designed NGC is able to guide neural outgrowths. 
The aim of the fifth study was the optimization and characterization of the beforementioned 
tubular structures for use as enzyme containers. The tubes should be analyzed in terms of swelling, 
chemical stability and molecular weight cut-off. The containers should be filled easily with various 
enzyme solutions and retain these enzymes inside, while still allowing the diffusion of their 
substrates, intermediates and products. The system should be established by using a single enzyme 
reaction. Later, an enzyme cascade should be mimicked by using two enzymes, each in a separate 
tube. 
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3 Synopsis 
This dissertation entails five publications and one manuscript showing a variety of 
applications using spider silk scaffolds in the field of biomedical engineering. It starts with a review 
about the use of the biomaterial ‘recombinant silk proteins’ in biomedical applications. The four 
following papers investigate the usability of spider silk scaffolds in tissue engineering. Two papers 
study the addition of possible additives to silk scaffolds to introduce either a sensitive biological 
substance or an antibacterial substance. The next two papers deal with the use of spider silk 
scaffolds for in vitro cell seeding. 2D spider silk films were investigated for cardiac tissue 
engineering and self-rolling bilayer structures for nerve regeneration. The last paper moves towards 
in vitro diagnostic tools and investigates the self-rolling bilayers as an enzyme container. A 
schematic overview is given in Figure 11.  
 
 
Figure 11: The dissertation starts in the middle of the spiral with a review about biomedical applications 
of recombinant silk proteins. The path goes on to silk with bioactive agents improving its usability in 
tissue engineering, namely active biological substances and antibacterial agents. Then the interaction of 
cells with spider silk scaffolds was investigated. Films underwent tests for heart muscle regeneration 
and self-rolling bilayers for nerve regeneration. These self-rolling bilayers were further analyzed for use 
as enzyme containers. 
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The first part of this dissertation is a review article (chapter 7, publication I, Biomedical 
Applications of Recombinant Silk-Based Materials). It provides a broad overview of the state of 
the art of recombinant silk-based materials in biomedical applications. Silk proteins have been 
transformed into various morphologies for use in regenerative medicine i.e. fibers, films, foams 
and hydrogels. Moreover, implant coatings seem a promising near-future application, whereas 
several drug delivery approaches using hydrogels, films, capsules and particles did not yet made 
the translation into clinics. 
The second part is a publication (chapter 7, publication III, Aqueous electrospinning of 
recombinant spider silk proteins). A completely aqueous process for electrospinning and post-
treatment of spider silk nonwoven mats was developed. The nonwoven mats were compared to 
conventional spun nonwoven mats in terms of morphology, secondary structure content and 
thermal behavior. The structural sensitive green fluorescent protein (GFP) and eADF4(C16) 
genetically modified with GFP were successfully encapsulated. Both kept their activity and the 
release could be studied. 
The third part is a manuscript (chapter 7, manuscript I, Enhanced antibacterial activity of 
Se nanoparticles upon coating with recombinant spider silk protein eADF4(κ16)) dealing with the 
coating of antibacterial selenium nanoparticles with eADF4(κ16) to increase the nanoparticle’s 
antibacterial effects against Gramm-negative bacteria. The size, charge and coating of the 
nanoparticles was characterized, before their effect on eukaryotic and prokaryotic cells was 
investigated. 
The fourth part consists of a publication (chapter 7, publication II, Surface Features of 
Recombinant Spider Silk Protein eADF4(κ16)-Made Materials are Well-Suited for Cardiac Tissue 
Engineering) dealing with the interaction of cardiac cells on eADF4(κ16) films. The water contact 
angle and the secondary structure content were determined. Then, cardiomyocytes were seeded and 
their response to the material under different external stimuli was examined to determine the 
materials suitability for cardiac TE. 
The fifth part of this work is a paper (chapter 7, publication V, Nerve Guidance Conduit 
Design based on Self-rolling Tubes). It analyses the suitability of self-rolled tubular structures 
filled with a silk film, aligned silk nonwoven mats and an anisotropic collagen cryogel as a nerve 
guidance conduit. The mechanical properties of the materials, their morphology and the response 
of a nerve cell line were analyzed. 
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The sixth part is a publication (chapter 7, publication IV, Self-Rolling Refillable Tubular 
Enzyme Containers Made of Recombinant Spider Silk and Chitosan). Self-rolling tubular 
structures were prepared, the swelling degree, the stability towards aqueous and organic solvents 
(SEM + gravimetric analysis) and the molecular weight cut-off (photometric) were determined. 
Then one- or two-tubes systems were created allowing the addition of one/two enzymes and 
analyzing their reactions. 
 
3.1 Scaffold with bioactive substance 
Here, an all-aqueous process was developed to prepare electrospun nonwoven meshes for 
mild encapsulation of active biological substances. Therefore, an aqueous solution of the 
recombinant silk protein eADF4(C16) was prepared at a high concentration and mixed with PEO 
to obtain the desired viscosity for spinning. A standard nonwoven mat prepared from HFIP solution 
was used as control. For this electrospinning process the silk polymer solution was transferred into 
a syringe connected to a pump. The needle was conducted with the collector plate, so that the droplet 
at the needle forms a Taylor cone by applying a high voltage. From this Taylor cone a liquid jet was 
accelerated towards the collector plate. The solvent evaporated in air and wipping instabilities lead 
to a random deposition of spider silk nanofibers onto the collector.264 After the spinning process the 
samples were subjected to different post-treatment methods using ethanol vapor or water annealing 
at different temperatures. Analysis of the materials using Fourier transform infrared spectroscopy 
(FTIR) with subsequent Fourier self-deconvolution (FSD) for secondary structure determination, 
differential scanning calorimetry (DSC) as well as scanning electron microscopy (SEM, Figure 12) 
showed no difference in secondary structure content (35.9 ± 1.3 % in all aqueous system and 38.6 
± 1.2 % in all organic system), the successful removal of PEG with post-treatment and a slight 
melting of the nonwovens in all aqueous processes, respectively.  
Green fluorescence protein (GFP) was used as a model for an active biological substance. It 
only fluoresces when its tertiary structure arranging the fluorophore is intact, allowing to easily 
analyze the destructive power of every step in the process. It could be shown that only an all aqueous 
system was able to retain its activity. GFP could be released from the nonwoven mat with a recovery 
rate of about 90 % within about 30 minutes. In order to avoid this burst release, a spider silk variant 
with genetically coupled GFP was incorporated into the nonwovens. This sample also showed a 
high activity after aqueous spinning and post-treatment, but no release of GFP was observed. Thus, 
the eADF4(C16) part of GFP-eADF4(C16) is fully integrated in the eADF4(C16) scaffold, whereby 
the structure of GFP was preserved. In future genetic modification of eADF4(C16) with different 
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signaling biologicals with an enzymatically cleavable linker could be imagined, enhancing the 
formation of new tissue. 
 
Figure 12: Electrospun nonwoven spider silk mat from aqueous solution with GFP. (a) SEM image of 
eADF4(C16) nonwoven mat spun from an aqueous solution and post-treated by water annealing at 
37 °C. The fibers slightly melted together, but can still be clearly distinguished from each other. (b) 
Inverted fluorescence scanner images of eADF4(C16) nonwovens with GFP electrospun from HFIP or 
aqueous solution after different post-treatment procedures. GFP was only active in all aqueous 
processes. (c) Cummulative GFP release over time of unbound GFP (C16AQ + GFP) as well as 
genetically coupled GFP (C16AQ + GFP-C16) from eADF4(C16) nonwoven mats. The unbound GFP 
was released within 30 minutes, no release was observed from the genetically coupled GFP over 
250 minutes. (d) Fluorescence microscope images of GFP release from unbound GFP (C16AQ + GFP) 
as well as genetically coupled GFP (C16AQ + GFP-C16). In the case of unbound GFP the picture was 
blurry already after 15 minutes proving a substantial release. After one day the GFP in the genetically 
coupled version was still active and clearly associated with the nonwoven mat. Reproduced (adapted) 
with permission.265 Copyright 2019, Elsevier GmbH. 
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3.2 Particles as antibacterial agent 
This study was performed to extend the scope of selenium nanoparticles (NPs) showing 
antibacterial properties against gram-positive bacteria towards gram-negative bacteria by applying 
a spider silk coating. The NPs were coated by mixing them into an aqueous eADF4(κ16) solution 
and subsequent washing (Figure 13). As a control, the NPs were coated with poly(vinyl alcohol) 
(PVA) in a similar fashion. TEM imaging proved a quite homogeneous size distribution of about 
46 nm in both cases. Energy dispersive spectroscopy (EDS) analysis as well as FTIR measurements 
proved the presence of silk. Further FSD analysis of the FTIR data proved to be in the desired β-
sheet rich secondary silk structure with 40.7 ± 0.8 %. The zeta potential of the NPs was determined 
to be positive in case of the silk coating (46.0 ± 0.6 mV) and slightly negative in case of the PVA 
coating (-7.3 ± 0.1 mV).  
Antibacterial tests using E. coli as a model for gram-negative bacteria showed, that the 
minimum bactericidal concentration of the silk coated NPs was 50 times lower than the that of the 
PVA coated NPs. The morphologies of E. coli after treatment determined by SEM explained this 
effect. The negatively charged cell wall of E. coli seemed to repel the negatively charged PVA NPs, 
whereby the silk coated NPs were attached to the bacterial cell wall. The silk coated NPs were 
further incorporated into eADF4(C16) and eADF4(κ16) films to avoid aggregation in nutrient-rich 
medium. Only the particles in the positively charged eADF4(κ16) film showed an antibacterial 
activity using colony forming units assay (Figure 13). This can presumably be attributed to the 
release of the silk coated NPs from the positive film due to electrostatic repulsion, which was 
confirmed by analyzing the supernatant with inductive coupled plasma-optical emission 
spectrometry (ICP-OES). 
The viability of Balb/3T3 fibroblasts and HaCaT keratinocytes in the presence of the NPs 
was investigated. PVA coated NPs showed no negative effect on fibroblasts, whereby silk coated 
NPs showed cytotoxic effects at four times the bactericidal dose. A cytotoxic effect in HaCaT was 
observed in both cases at the same concentration. This concentration corresponds to eight times the 
bactericidal dose in silk coated NPs, but to one eight of the bactericidal dose in PVA coated NPs. 
This study presents an alternative to antibiotics with the advantage, that up to now no prove was 
found, that bacteria can develop resistance against NPs. Especially hospitals are a hot spot for 
infections, so called healthcare associated infections with a considerable part of them being 
surgical-site infections.266 The silk coated NPs could be encapsulated in various scaffolds protecting 
the TE construct from bacterial infections avoiding after surgical complications. 
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Figure 13: Spider silk coated Se NPs. (a) TEM images of eADF4(κ16) coated Se NPs show a 
homogeneous size distribution. (b) Colony Forming unit (CFU) of E. coli of eADF4(κ16) coated Se NPs 
encapsulated in eADF4(κ16) and eADF4(C16) films compared to the films without NPs. Only the 
eADF4(κ16) film with coated NPs reduced the CFU. (c-f) SEM images of E. coli without (c & e) and 
treated with (d & f) silk coated Se NPs clearly attacking the bacteria. (g) Agar plate of CFU tests with 
E. coli incubated with different amounts of silk coated Se NPs. At 15.6 µg/ml no colonies were found 
at any E. coli concentration applied. 
 
3.3 Heart muscle regeneration 
The third study was devoted to heart muscle regeneration. The cellular behavior of primary 
cardiac cells from 3-days-old Sprague-Dawley rats on eADF4(κ16) films was investigated and 
compared to fibronectin (positive control) and gelatin (neutral control) coating. The silk films were 
prepared by a dip-coating process. For the positively charged eADF4(κ16), cleaned glass coverslips 
were dipped into an eADF4(κ16) solution in formic acid and dried on parafilm to enable a complete 
coverage of the coverslips avoiding delamination during cell culture.  
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The films were characterized using water contact angle measurements and secondary 
structure determination via FTIR with FSD. The water contact angle of the eADF4(κ16) film  was 
38 ± 9 ° Thus, the silk rendered glass more hydrophilic and lay in a similar range than gelatin 
(29 ± 7 °). The β-sheet content is an important measure of crystallinity of the silk and hence, the 
physicochemical properties like water solubility. The β-sheet content commonly lies between 10 % 
and 45 % and mainly depends on the preparation method. A value below 20 % leads to water soluble 
structures (data not shown). The silk film possessed a β-sheet content of 33.6 ± 0.6 %, hence clearly 
above 20 % and was water-insoluble. 
Cell studies showed that spider silk films are nontoxic and cardiomyocytes as well as 
endothelial cells and fibroblasts attached to them. On eADF4(κ16) films cardiomyocytes adhered 
better than the other cell types investigated. This could be beneficial in artificial constructs, as 
compared to cardiomyoctes all other cell types are proliferating. Cardiomyocyte proliferation could 
be stimulated by the addition of fetal bovine serum (FBS) or fibroblast growth factor 1 (FGF1)/p38 
inhibitor (p38i). An interesting feature of silk films was that they, in comparison with fibronectin, 
did not induce hypertrophy, which was only observed under the addition of stimulating factors like 
FBS or phenylephrine (PE). Hypertrophy is the increase of cell size and in the heart commonly 
induced by hormones like in pregnancy. Hypertrophy induced without stimulating factors can lead 
to pathological hypertrophy.267 
In order to provide proper contractility, well-differentiated as well as aligned sarcomers are 
important, which could be seen on silk and fibronectin films. Contractility analysis demonstrated 
that cardiomyocytes beat with a comparable frequency and possessed a similar amplitude on silk 
and on fibronectin films. Cardiomyocytes on eADF4(κ16) films were further analyzed in terms of 
cell-to-cell communication and electric coupling. Connexin 43 is a gap-junction protein associated 
with cell-to-cell communication and staining proved its presence in cardiomyocytes cultured on 
eADF4(κ16) and fibronectin. Calcium homeostasis gives an important hint about electric coupling 
of cardiomyocytes, what is an important factor for proper host integration. Calcium imaging of 
eADF4(κ16) and fibronectin films showed excitation waves going through the samples with a 
comparable rate and amplitude. (Figure 14)  
Spider silk films proved to be non-toxic, showed no pharmacological effect and 
cardiomyocytes grown on these films exhibited proper excitation propagation and responded 
properly to extracellular stimuli. Future tests should aim at testing these primary cells in 3D 
environment like encapsulated in hydrogels, a morphology that cannot be formed with fibronectin. 
Moreover, stem cell behavior on silk materials could be investigated, before first in vivo studies are 
planned.  The addition of the beforementioned additives could further increase the success of silk 
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scaffolds in cardiac regeneration. Another possible route for such tissue mimicking materials is drug 
screening, which could allow a reduction of patients in clinical studies. 
 
 
Figure 14: Cardiomyocytes cultured on eADF4(κ16) and fibronectin films. (a, b) Cardiac cells seeded 
on eADF4(κ16) and fibronectin films with 0.2 % (a) and 10 % (b) stimulation with fetal bovine serum 
(FBS). The cells were stained for sarcomeric-α-actinin (green), showing well-differentiated sarcomeres, 
whose alignment is beneficial in contraction. The staining of the gap junction protein connexin-43 (red) 
proposes cell-to-cell communication (yellow arrows) and nuclei were stained with Hoechst (blue). 
Fibronectin induces hypertrophy, therefore, the cells look similar in size in low and high FBS, whereby 
the silk allowed for stimulation of hypertrophy upon the addition of stimulating factors like FBS. Thus, 
the cells showed an increase in size in the high FBS compared to low FBS concentrations. (c) Beats per 
minute were comparable in both samples. (d, e) Calcium imaging records the change in calcium 
concentration in cardiac cells during contraction. The number of contractions as well as the frequency 
thereof was the same on both materials. Reproduced (adapted) with permission.268 Copyright 2017, 
WILEY-VCH Verlag GmbH & Co. 
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3.4 Nerve regeneration 
An adaptable tubular system for use as nerve guidance conduit (NGC) made of biodegradable 
self-rolling tubes was developed. The self-rolling mechanism allows to not only modify the inner 
surface, but in addition provides a gentle way to encapsulate sensitive substances. Here, this 
advantage was taken to line chitosan tubes with an eADF4(C16)-RGD film or aligned eADF4(C16) 
fibers-mat and to encapsulate anisotropic cryogels. The PC-12 nerve cell line was gently 
encapsulated by the rolling process and allowed to grow and differentiate in these three different 
types of tubes (Figure 15).  
The tubes lined with an eADF4(C16)-RGD film were prepared by successive casting of the 
silk and chitosan. For the other two constructs a chitosan film was cast. The aligned eADF4(C16) 
fiber-mat was electrospun directly onto the chitosan film. The anisotropic collagen cryogel was 
simply applied on the film before rolling was induced. The self-rolling process was initiated by the 
addition of any aqueous solution and took a few seconds only. This simple preparation of these 
tubes did not require the addition of possible harmful crosslinkers. 
An anisotropic collagen cryogel offers a longitudinal porous structure in which nerve cells 
are guided to the posterior end. The cryogel is produced by unidirectional cryogelation. Here, an 
acidic aqueous collagen solution was mixed with the crosslinker glutaraldehyde. Then the solution 
was transferred to an insulated tube and placed on top of a copper plate and put into a freezer. Ice 
crystals started to grow from the copper plate to the top of the tube. This caused the collagen and 
crosslinker solution to concentrate, enabling the reaction of the two materials. The ice crystals acted 
as a porogen, which could be removed by thawing and the excess of glutaraldehyde could be 
removed by washing with glycine, leaving a crosslinked collagen network with longitudinal-
oriented structures (Figure 15). 
Mechanical testing was performed and the tensile stress, maximum strain and Young’s 
modulus of the moisturized chitosan film were determined to be 47 ± 17 MPa, 101 ± 24 % and 30 
± 13 MPa and of the moist collagen cryogels (longitudinal) 0.15 ± 0.035 MPa, 65 ± 11 % and 0.2 
± 0.055 MPa. Both materials showed long ranging linear elastic deformations. The chitosan film 
had a sharp rupture point, whereby the collagen cryogels illustrated a gradual deformation 
continuing up to 300 % strain. Worth to mention here, the mechanical properties of the collagen 
cryogels were in the range of healthy peripheral nerves.192 
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Figure 15: Nerve guidance conduit (NGC) preparation: Chitosan film is modified with either an 
eADF4(C16)-RGD film, an eADF4(C16) aligned nonwoven or with an anisotropic collagen cryogel. 
The cryogel is prepared using directional freezing combined with glutaraldehyde crosslinking. The tubes 
are allowed to roll in nerve cell suspension, thereby encapsulating the PC-12 cells. The cells are then 
differentiated in the tubes. The pictures on the right side show examples of immunostained PC-12 cells  
after differentiation in the respective NGCs – cells were stained for β-III tubulin, a microtubule forming 
protein, which is present in differentiated cells only (green) and nuclei with Hoechst (blue). Reproduced 
(adapted) with permission.269 Copyright 2020, Elsevier GmbH. 
 
The interaction of PC-12 nerve cells was investigated on all materials used. The cells adhered 
and proliferated on eADF4(C16)-RGD films, eADF4(C16) nonwoven mats as well as on collagen 
cryogel. Then the differentiation potential was tested on these promising materials and it was found, 
that the cells could be differentiated directly on them. In a last step, NGCs were prepared by 
allowing the tubes to self-roll in a PC-12 cell suspension for encapsulation. In the case of the 
cryogel, the cell suspension was soaked up and then chitosan was allowed to roll around it. Cells 
were able to attach to the provided inner surface and differentiate upon the addition of 
differentiation media. Neurite like outgrowths were formed, which could be detected by 
immunostaining. It could further be shown, that the neurites accepted the internal structure, as they 
grew in all directions in the case of eADF4(C16)-RGD films but followed the structure of aligned 
eADF4(C16) nonwovens or anisotropic collagen cryogels (Figure 15). Surprisingly, the outgrowths 
in collagen cryogels formed even bundle like structures.  
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For future experiments one could imagine testing of primary or stem cells or even first in vivo 
tests, bridging artificial nerve defects like sciatic nerve in rats. Also adding the beforementioned 
additives could help improving the performance of the NGCs. Especially a gradual addition of nerve 
growth factor could trigger the outgrowth of the axons at the proximal stump into the NGC. 
 
3.5 Enzyme containers 
Self-rolling tubular structures can be further applied as enzyme containers using a bilayer 
made of recombinant spider silk protein eADF4(C16) and chitosan. Silk films showed only little 
swelling by AFM analysis (9.9 ± 8.3 %), whereas chitosan absorbed 250 ± 20 % of its dry weight 
in water. The tubes were prepared by allowing the bilayer to roll around a needle in PBS for five 
seconds. After drying, the needle was removed, and a stable tube was obtained. The dimension of 
the container could be adjusted by e.g. using needles with various diameters. The tubes were shown 
to be stable in biologically relevant organic solvents and in aqueous buffers with pH ranging from 
3 to 11. Scanning electron microscopy (SEM) showed no delamination of the layers upon rolling. 
 The tubes were glued into tissue culture plates to create biodegradable containers for one-
pot enzymes reactions. The enzymes could be pipetted inside of the tubes, hence neither genetical 
modification nor immobilization on solid carriers was required avoiding hampered enzyme activity. 
With a molecular weight cut-off above 20,000 g/mol the semi-permeable tube wall retained the 
enzymes inside of the tube and allowed substrates and/or products to diffuse. Thus, the surrounding 
reaction media could be exchanged, or the product harvested, without the need to change or remove 
the often costly enzyme. The suitability of the system was shown with esterase-2 using p-
nitrophenyl acetate as a substrate. Therefore, the tube was loaded with enzyme solution and the 
reaction mixture was added to the surrounding. Product was detected in the surrounding medium, 
thus, the substrate was able to diffuse in and the product to diffuse out of the tube. The reaction rate 
and enzyme activity were lower than in the positive control (free enzyme in solution) presumably 
due to the required double diffusion.  
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Figure 16: Two-tube system. A stimuli responsive bilayer made of chitosan (active polymer) and 
eADF4(C16) (passive polymer) was allowed to roll around a needle in PBS. After drying, the needle 
was removed, the tube cut to desired length and two of these tubes glued into one well of a tissue culture 
well plate. Each tube was then filled with an enzyme (E1 and E2) and the solution containing the 
substrate (S) for E1 was added to the surrounding. This substrate then diffused into tube 1, where it 
reacted with E1 forming an intermediate = substrate (I) for E2. In tube 2 I was then converted by E2 
into the product, which then either stayed in the tube or diffused outside. Exemplarily a graph of c-
fluorescein degradation by glucose oxidase (GOX) and horseradish peroxidase (HRP) is shown. The 
positive control showed a faster degradation than in the two-tube system, probably due to the diffusion 
time. But the reaction stopped after 180 min in the positive control, whereby the degradation continued 
up to 240 min in the two-tube system (* significantly different, # not significantly different, t-test: 
p < 0.05). Reproduced (adapted) with permission.270 Copyright 2019, ACS Publications. 
 
Further, an enzyme cascade was mimicked using a two-tube system with the coupled 
reaction of glucose oxidase (GOX) and horseradish peroxidase (HRP) using either 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) or carboxy-fluorescein as a substrate (Figure 16). 
In the case of ABTS, the product was captured inside of the HRP-tube. Thus, the substrate and 
intermediate were able to diffuse through the tube walls, but the product was hindered. The product 
is a radical cation and therefore, is prone to react with or stick to the tube. Such a system could be 
beneficial, if such species should be removed from a solution. Carboxy-fluorescein was successfully 
degraded by GOX and HRP in the two-tube system. Due to the necessity of diffusion of substrates, 
intermediates and products, the reaction rate was slowed down as already observed in the one-tube 
system. Nevertheless, the two-tube system enabled a longer reaction time than the control (240 min 
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vs. 180 min), presumably due to protection of the enzyme from H2O2. Furthermore, the surrounding 
media could be exchanged without decrease in enzyme activity. This system could be imagined as 
a biological recognition element of a biosensor. Moreover, cells could be encapsulated to analyze 
their metabolic products in changeable environments. 
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